Vendor Neutral Archive (VNA) & PACS Market by Product Type (Department, Multi-department, Multi-site), Modality (CT, MRI, X-ray, Ultrasound, Mammo), Application (Cardio, Onco, Neuro), End User (Hospital, ASC, Diagnostic Center) - Global Forecast to 2031
The VNA & PACS market is projected to reach USD 8.57 billion by 2031 from USD 5.60 billion in 2026, at a CAGR of 8.9%. The VNA & PACS market is seeing an increase in demand due to the evolution in the delivery of healthcare services, in which providers need imaging platforms that help coordinate care in hospitals, clinics, and diagnostic facilities. The adoption of a data-centric healthcare model has increased the demand for imaging records, which would allow clinicians to gain access to patients’ medical history and help with diagnosis and treatment plans. In addition to this, there is a demand for outpatient imaging centers, which need cloud-based PACS and VNA systems to support their imaging processes. Also, the rise in the adoption of software as a service (SaaS) business models by vendors has influenced the strategies of providers who look for flexible options and less expensive total cost of ownership models. This demand is further supported by the recent mergers and acquisitions in the industry, such as Intelerad Medical Systems Incorporated (Canada) acquired by GE HealthCare (US) in March 2026.
“By product type, the VNA segment accounted for the largest share of the VNA & PACS market in 2025.”
By type of product, the VNA category will dominate the VNA & PACS market in 2025 since it provides healthcare institutions with the ability to centrally manage imaging data and ensure the sustainability of their IT infrastructure through interoperability among different systems. Through VNAs, healthcare providers can separate their data from their proprietary PACS and allow for easy information exchange without compromising system dependency issues. As stated by the Healthcare Information and Management Systems Society (2023), health facilities are shifting towards an enterprise imaging approach that stresses interoperable and vendor-neutral infrastructure to promote better patient care and improve the accessibility of their information. Similarly, according to the European Society of Radiology, long-term archiving of images and cross-enterprise data exchange have become fundamental in radiology practices today. Recent industry trends indicate that Hyland Software, Inc. (US) is developing its cloud-based VNA solution in 2025 to meet the demands of large-scale enterprises.
“By vendor type, the third-party vendor segment is expected to have the fastest growth during the forecast period.”
Based on vendor type, the VNA & PACS market is segmented into independent vendors and third-party vendors. The third-party vendor market is projected to experience the highest rate of growth during the forecasted period, mainly owing to the growing demand for interoperability among different healthcare IT environments. Third-party vendors are involved in offering solutions that ensure interoperability among PACS, VNA, EHR, and various other clinical software applications so that healthcare organizations are able to integrate all of their data while maintaining their current infrastructure. As stated in a study conducted by Radsource in January 2025, PACS interoperability helps healthcare institutions become more efficient in the workflow process and improve overall patient care by exchanging data with other health systems. A recent development that shows the importance of PACS interoperability involves the enhancement of interoperable data management solutions by BridgeHead Software Ltd. (UK) and PaxeraHealth Corp. (US).
“APAC will witness the highest growth rate during the forecast period.”
The VNA & PACS Market in the Asia Pacific region is witnessing robust growth due to increased spending on healthcare infrastructure, swift digitization of hospitals, and the escalating need for imaging diagnostics in a large number of patients. The governments in the region are aggressively implementing digital health strategies at the national level to facilitate better data exchange and accessibility. As per the report published by the World Health Organization (2021), nations in the Asia Pacific region are fast-tracking their digital health technology adoption to optimize the efficiency and delivery of services in health systems. Furthermore, the development of hospital chains and increased usage of electronic medical records are driving a high demand for comprehensive imaging data management systems. For example, FUJIFILM Holdings Corporation (Japan) is expanding its enterprise imaging solutions in Asia Pacific in 2025, whereas Canon Medical Systems Corporation (Japan) upgraded its imaging informatics offerings in 2025.
The breakdown of primary participants is as given below:
This research report categorizes the VNA & PACS Market by Product Type (VNA [Department VNA, Multi-Department VNA, Multi-Site VNA], PACS [Department PACS, Multi-Department PACS, Multi-Site PACS]) | VNA & PACS Market, by Modality (CT, Mammography, MRI, Ultrasound, X-Rays, PET) | VNA & PACS Market, by Deployment (On-Premise Deployment, Cloud-Based Deployment, Hybrid Deployment) | VNA & PACS Market, by Vendor Type (Independent Vendor, Third-Party Vendor) | VNA & PACS Market, by Application (Cardiology, Orthopedic, Oncology, Neurology, Obstetrics and Gynecology, Other Applications) | VNA & PACS Market, by End User (Hospitals & Clinics, Diagnostic Centers, Ambulatory Surgical Centers, Other End Users) and region (North America, Europe, Asia Pacific, Latin America, and Middle East & Africa). The scope of the report covers detailed information regarding the major factors, such as drivers, restraints, challenges, and opportunities, influencing the growth of the VNA PACS market. A detailed analysis of the key industry players has been done to provide insights into their business overview, solutions, and services; key strategies; contracts, partnerships, agreements, new product & service launches, mergers & acquisitions, and recent developments associated with the VNA PACS market. Competitive analysis of upcoming startups in the VNA PACS market ecosystem is covered in this report.
Reasons to buy this report
The report will help the market leaders/new entrants in this market with information on the closest approximations of the revenue numbers for the VNA & PACS market and the subsegments. This report will help stakeholders understand the competitive landscape and gain more insights to better position their businesses and plan suitable go-to-market strategies. The report also helps stakeholders understand the pulse of the market and provides them with information on key market drivers, restraints, challenges, and opportunities.
The report provides insights into the following pointers:
“By product type, the VNA segment accounted for the largest share of the VNA & PACS market in 2025.”
By type of product, the VNA category will dominate the VNA & PACS market in 2025 since it provides healthcare institutions with the ability to centrally manage imaging data and ensure the sustainability of their IT infrastructure through interoperability among different systems. Through VNAs, healthcare providers can separate their data from their proprietary PACS and allow for easy information exchange without compromising system dependency issues. As stated by the Healthcare Information and Management Systems Society (2023), health facilities are shifting towards an enterprise imaging approach that stresses interoperable and vendor-neutral infrastructure to promote better patient care and improve the accessibility of their information. Similarly, according to the European Society of Radiology, long-term archiving of images and cross-enterprise data exchange have become fundamental in radiology practices today. Recent industry trends indicate that Hyland Software, Inc. (US) is developing its cloud-based VNA solution in 2025 to meet the demands of large-scale enterprises.
“By vendor type, the third-party vendor segment is expected to have the fastest growth during the forecast period.”
Based on vendor type, the VNA & PACS market is segmented into independent vendors and third-party vendors. The third-party vendor market is projected to experience the highest rate of growth during the forecasted period, mainly owing to the growing demand for interoperability among different healthcare IT environments. Third-party vendors are involved in offering solutions that ensure interoperability among PACS, VNA, EHR, and various other clinical software applications so that healthcare organizations are able to integrate all of their data while maintaining their current infrastructure. As stated in a study conducted by Radsource in January 2025, PACS interoperability helps healthcare institutions become more efficient in the workflow process and improve overall patient care by exchanging data with other health systems. A recent development that shows the importance of PACS interoperability involves the enhancement of interoperable data management solutions by BridgeHead Software Ltd. (UK) and PaxeraHealth Corp. (US).
“APAC will witness the highest growth rate during the forecast period.”
The VNA & PACS Market in the Asia Pacific region is witnessing robust growth due to increased spending on healthcare infrastructure, swift digitization of hospitals, and the escalating need for imaging diagnostics in a large number of patients. The governments in the region are aggressively implementing digital health strategies at the national level to facilitate better data exchange and accessibility. As per the report published by the World Health Organization (2021), nations in the Asia Pacific region are fast-tracking their digital health technology adoption to optimize the efficiency and delivery of services in health systems. Furthermore, the development of hospital chains and increased usage of electronic medical records are driving a high demand for comprehensive imaging data management systems. For example, FUJIFILM Holdings Corporation (Japan) is expanding its enterprise imaging solutions in Asia Pacific in 2025, whereas Canon Medical Systems Corporation (Japan) upgraded its imaging informatics offerings in 2025.
The breakdown of primary participants is as given below:
- By Company Type - Tier 1: 40%, Tier 2: 35%, and Tier 3: 25%
- By Designation - C-level: 42%, Director-level: 31%, and Others: 27%
- By Region - North America: 35%, Europe: 30%, Asia Pacific: 25%, Latin America: 6%, Middle East & Africa: 5%
- The study includes an in-depth competitive analysis of these key players in the VNA PACS market, with their company profiles, recent developments, and key market strategies.
This research report categorizes the VNA & PACS Market by Product Type (VNA [Department VNA, Multi-Department VNA, Multi-Site VNA], PACS [Department PACS, Multi-Department PACS, Multi-Site PACS]) | VNA & PACS Market, by Modality (CT, Mammography, MRI, Ultrasound, X-Rays, PET) | VNA & PACS Market, by Deployment (On-Premise Deployment, Cloud-Based Deployment, Hybrid Deployment) | VNA & PACS Market, by Vendor Type (Independent Vendor, Third-Party Vendor) | VNA & PACS Market, by Application (Cardiology, Orthopedic, Oncology, Neurology, Obstetrics and Gynecology, Other Applications) | VNA & PACS Market, by End User (Hospitals & Clinics, Diagnostic Centers, Ambulatory Surgical Centers, Other End Users) and region (North America, Europe, Asia Pacific, Latin America, and Middle East & Africa). The scope of the report covers detailed information regarding the major factors, such as drivers, restraints, challenges, and opportunities, influencing the growth of the VNA PACS market. A detailed analysis of the key industry players has been done to provide insights into their business overview, solutions, and services; key strategies; contracts, partnerships, agreements, new product & service launches, mergers & acquisitions, and recent developments associated with the VNA PACS market. Competitive analysis of upcoming startups in the VNA PACS market ecosystem is covered in this report.
Reasons to buy this report
The report will help the market leaders/new entrants in this market with information on the closest approximations of the revenue numbers for the VNA & PACS market and the subsegments. This report will help stakeholders understand the competitive landscape and gain more insights to better position their businesses and plan suitable go-to-market strategies. The report also helps stakeholders understand the pulse of the market and provides them with information on key market drivers, restraints, challenges, and opportunities.
The report provides insights into the following pointers:
- Analysis of key drivers (Heightened investments in medical imaging technologies, Growing demand for streamlined healthcare data management solutions, Integration of PACS/VNA with electronic medical records) restraints (High initial investment for implementing VNA and PACS solutions, Lack of standardized protocols and interoperability frameworks) opportunities (InFavorable government initiatives for better penetration of Al in medical imaging, Increasing medical imaging procedures and large imaging data silos, Rapid uptake of big data in healthcare) challenges (Rising security concerns related to cloud-based image processing and analytics, Data security issues in healthcare settings) influencing the growth of the VNA PACS market
- Product Development/Innovation: Detailed insights on upcoming technologies, research & development activities, and new product & service launches in the VNA & PACS Market
- Market Development: Comprehensive information about lucrative markets; the report analyses the VNA PACS market across varied regions.
- Market Diversification: Exhaustive information about new products & services, untapped geographies, recent developments, and investments in the VNA & PACS Market
- Competitive Assessment: In-depth assessment of market shares, growth strategies, and service offerings of leading players like FUJIFILM Holdings Corporation (Japan), GE HealthCare (US), Merative (US), Sectra AB (Sweden), Siemens Healthineers AG (Germany), BridgeHead Software Ltd. (UK), among others, in the VNA PACS market
1 INTRODUCTION
1.1 STUDY OBJECTIVES
1.2 MARKET DEFINITION
1.3 STUDY SCOPE
1.3.1 MARKET SEGMENTATION AND REGIONAL SCOPE
1.3.2 INCLUSIONS AND EXCLUSIONS
1.3.3 YEARS CONSIDERED
1.4 CURRENCY CONSIDERED
1.5 STAKEHOLDERS
2 EXECUTIVE SUMMARY
2.1 KEY INSIGHTS AND MARKET HIGHLIGHTS
2.2 KEY MARKET PARTICIPANTS: MAPPING OF STRATEGIC DEVELOPMENTS
2.3 DISRUPTIVE TRENDS SHAPING VNA & PACS MARKET
2.4 HIGH-GROWTH SEGMENTS
2.5 REGIONAL SNAPSHOT: MARKET SIZE, GROWTH RATE, AND FORECAST
3 PREMIUM INSIGHTS
3.1 ATTRACTIVE OPPORTUNITIES FOR VENDOR NEUTRAL ARCHIVE (VNA) & PACS MARKET
3.2 NORTH AMERICA VNA PACS MARKET, BY END USER AND COUNTRY
3.3 VENDOR NEUTRAL ARCHIVE (VNA) & PACS MARKET, BY COUNTRY
4 MARKET OVERVIEW
4.1 INTRODUCTION
4.2 MARKET DYNAMICS
4.2.1 DRIVERS
4.2.1.1 Heightened investments in medical imaging technologies
4.2.1.2 Growing demand for streamlined healthcare data management solutions
4.2.1.3 Integration of PACS/VNA with Electronic Medical Records (EMRs)
4.2.2 RESTRAINTS
4.2.2.1 High initial investment
4.2.2.2 Lack of standardized protocols and interoperability frameworks
4.2.3 OPPORTUNITIES
4.2.3.1 Government initiatives to increase penetration of AI in medical imaging
4.2.3.2 Increasing medical imaging procedures and large imaging data silos
4.2.3.3 Rapid uptake of big data in healthcare
4.2.4 CHALLENGES
4.2.4.1 Rising security concerns related to cloud-based image processing and analytics
4.2.4.2 Data security issues
4.3 UNMET NEEDS AND WHITE SPACES
4.4 INTERCONNECTED MARKETS AND CROSS-SECTOR OPPORTUNITIES
4.5 STRATEGIC MOVES BY TIER-1/2/3 PLAYERS
5 INDUSTRY TRENDS
5.1 PORTER’S FIVE FORCES ANALYSIS
5.1.1 INTENSITY OF COMPETITIVE RIVALRY
5.1.2 BARGAINING POWER OF SUPPLIERS
5.1.3 BARGAINING POWER OF BUYERS
5.1.4 THREAT OF NEW ENTRANTS
5.1.5 THREAT OF SUBSTITUTES
5.2 MACROECONOMICS INDICATORS
5.2.1 INTRODUCTION
5.2.2 GDP TRENDS AND FORECAST
5.2.3 TRENDS IN GLOBAL HEALTHCARE IT INDUSTRY
5.3 VALUE CHAIN ANALYSIS
5.4 ECOSYSTEM MAPPING
5.5 PRICING ANALYSIS
5.5.1 AVERAGE SELLING PRICE (ASP) TREND OF VNA AND PACS SOLUTIONS, BY PRODUCT TYPE
5.5.2 AVERAGE SELLING PRICE TREND, BY REGION
5.6 KEY CONFERENCES AND EVENTS, 2026–2027
5.7 TRENDS/DISRUPTIONS IMPACTING CUSTOMER BUSINESS
5.8 INVESTMENT AND FUNDING SCENARIO
5.9 CASE STUDY ANALYSIS
5.9.1 AMBRA HEALTH UTILIZED AWS CLOUD SERVICES TO PROPEL WORLDWIDE GROWTH OF ITS MEDICAL IMAGING PLATFORM
5.9.2 NHS TRUST ADOPTED INTEGRATION AND INSTANT DATA ACCESS OFFERED BY SYNAPPS VNA TO ESTABLISH UNIFIED PLATFORM FOR STORING AND MANAGING DICOM IMAGE DATA
5.10 IMPACT OF 2025 US TARIFF OVERVIEW
5.10.1 INTRODUCTION
5.10.2 KEY TARIFF RATES
5.10.3 PRICE IMPACT ANALYSIS
5.11 IMPACT ON COUNTRY/REGION
5.11.1 THE US
5.11.2 EUROPE
5.11.3 APAC
5.12 IMPACT ON END USE INDUSTRIES
5.13 CONCLUSION
6 TECHNOLOGICAL ADVANCEMENTS, AI-DRIVEN IMPACT, PATENTS, INNOVATIONS, AND FUTURE APPLICATIONS
6.1 KEY EMERGING TECHNOLOGIES
6.1.1 DICOM (DIGITAL IMAGING AND COMMUNICATIONS IN MEDICINE)
6.1.2 ENTERPRISE IMAGING SOLUTIONS
6.1.3 CLOUD-BASED STORAGE AND SERVICES
6.2 COMPLEMENTARY TECHNOLOGIES
6.2.1 IMAGE EXCHANGE NETWORKS
6.2.2 DATA ANALYTICS AND BUSINESS INTELLIGENCE
6.3 ADJACENT TECHNOLOGIES
6.3.1 HEALTH INFORMATION EXCHANGE (HIE)
6.4 PATENT ANALYSIS
6.4.1 INSIGHTS: JURISDICTION AND TOP APPLICANT ANALYSIS
6.5 FUTURE APPLICATIONS
6.5.1 AI-ENABLED ENTERPRISE DIAGNOSTIC ORCHESTRATION
6.5.2 MULTI-SPECIALTY ENTERPRISE IMAGING REPOSITORY
6.5.3 IMAGING DATA LAKE FOR CLINICAL RESEARCH AND REAL-WORLD EVIDENCE
6.5.4 CLOUD-BASED REGIONAL IMAGE EXCHANGE AND VIRTUAL CARE NETWORKS
6.5.5 PERSONALIZED AND LONGITUDINAL IMAGING INTELLIGENCE
7 REGULATORY LANDSCAPE
7.1 REGIONAL REGULATIONS AND COMPLIANCE
7.1.1 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
7.1.2 REGULATIONS
7.1.2.1 US
7.1.2.2 Europe
7.1.2.3 China
7.1.2.4 Japan
7.1.2.5 India
7.1.3 INDUSTRY STANDARDS
8 CUSTOMER LANDSCAPE & BUYER BEHAVIOR
8.1 INTRODUCTION
8.2 DECISION-MAKING PROCESS
8.3 BUYER STAKEHOLDERS AND BUYING EVALUATION CRITERIA
8.3.1 KEY STAKEHOLDERS IN BUYING PROCESS
8.3.2 BUYING CRITERIA
8.4 ADOPTION BARRIERS & INTERNAL CHALLENGES
8.5 UNMET NEEDS FROM VARIOUS END-USE INDUSTRIES
8.5.1 UNMET NEEDS
8.5.2 END-USER EXPECTATIONS
8.6 MARKET PROFITABILITY
9 VENDOR NEUTRAL ARCHIVE (VNA) & PACS MARKET, BY PRODUCT TYPE
9.1 INTRODUCTION
9.2 VNA
9.2.1 DEPARTMENT VNA
9.2.1.1 Phased imaging modernization driving VNA adoption and interoperability growth
9.2.2 MULTI-DEPARTMENT VNA
9.2.2.1 Cross-department imaging consolidation driving scalable enterprise data platform adoption
9.2.3 MULTI-SITE VNA
9.2.3.1 Cloud-based multi-site imaging consolidation enabling scalable, centralized care delivery
9.3 PACS
9.3.1 DEPARTMENT PACS
9.3.1.1 Rising imaging volumes and workforce shortages driving workflow-centric PACS adoption
9.3.2 MULTI-DEPARTMENT PACS
9.3.2.1 Shared imaging platforms reducing silos and enabling cross-specialty collaboration
9.3.3 MULTI-SITE PACS
9.3.3.1 Centralized cloud PACS enabling cross-site workload balancing and productivity gains
10 VENDOR NEUTRAL ARCHIVE (VNA) & PACS MARKET, BY MODALITY
10.1 INTRODUCTION
10.2 CT
10.2.1 RAPID RISE IN NEED FOR CT EXAMINATIONS TO SUPPORT MARKET GROWTH
10.3 MAMMOGRAPHY
10.3.1 RISE IN NUMBER OF MAMMOGRAPHY PROCEDURES TO DRIVE MARKET GROWTH
10.4 ULTRASOUND
10.4.1 RISING TECHNOLOGICAL ADVANCEMENT IN ULTRASOUND DEVICES TO SUPPORT MARKET GROWTH
10.5 MAGNETIC RESONANCE IMAGING (MRI)
10.5.1 MRI IS COST-EFFECTIVE AND EASILY AVAILABLE COMPARED TO PET
10.6 X-RAY
10.6.1 RAPID ADOPTION OF X-RAY IMAGING COMPARED TO OTHER MODALITIES TO BOOST MARKET
10.7 PET
10.7.1 INCREASING USE OF NUCLEAR MEDICINES TO SUPPORT POPULARITY OF PET
11 VENDOR NEUTRAL ARCHIVE (VNA) & PACS MARKET, BY DEPLOYMENT MODEL
11.1 INTRODUCTION
11.2 ON-PREMISE MODEL
11.2.1 ON-PREMISE DEPLOYMENT MODEL PROVIDES HEALTHCARE ORGANIZATIONS WITH GREAT CONTROL AND SECURITY OVER SENSITIVE PATIENT DATA
11.3 CLOUD-BASED MODEL
11.3.1 TECHNOLOGICAL ADVANCEMENTS IN DIAGNOSTIC IMAGING MODALITIES TO DRIVE CLOUD-BASED MODEL’S POPULARITY
11.4 HYBRID MODEL
11.4.1 UNIFIED EFFICIENCY FOR OPTIMAL PERFORMANCE TO DRIVE HYBRID VNA AND PACS SOLUTIONS
12 VENDOR NEUTRAL ARCHIVE (VNA) & PACS MARKET, BY VENDOR TYPE
12.1 INTRODUCTION
12.2 INDEPENDENT VENDOR
12.2.1 DOMINANCE OF INDEPENDENT VENDORS TO CAPTURE SIGNIFICANT MARKET SHARE
12.3 THIRD-PARTY VENDOR
12.3.1 NEED FOR INNOVATIVE SOLUTIONS TO FUEL SURGE IN THIRD-PARTY VENDORS’ PRESENCE IN MARKET
13 VENDOR NEUTRAL ARCHIVE (VNA) & PACS MARKET, BY APPLICATION
13.1 INTRODUCTION
13.2 CARDIOLOGY
13.2.1 RISING CASES OF CARDIAC DISORDERS TO DRIVE MARKET
13.3 ORTHOPEDIC
13.3.1 GROWTH IN CASES OF ARTHRITIS TO SUPPORT MARKET GROWTH
13.4 ONCOLOGY
13.4.1 RISE IN NUMBER OF CANCER CASES TO DRIVE USE OF VNA AND PACS SOLUTIONS FOR ONCOLOGY
13.5 NEUROLOGY
13.5.1 INCREASING DEMAND FOR ADVANCED NEUROLOGICAL IMAGING TECHNOLOGIES TO SPUR GROWTH
13.6 OBSTETRICS & GYNECOLOGY
13.6.1 USE OF 3D AND 4D IMAGING FOR MONITORING FETUS GROWTH AND DIAGNOSING HIGH-RISK PREGNANCIES TO DRIVE APPLICATION OF VNA AND PACS SOLUTIONS
13.7 OTHER APPLICATIONS
14 VENDOR NEUTRAL ARCHIVE (VNA) & PACS MARKET, BY END USER
14.1 INTRODUCTION
14.2 HOSPITALS & CLINICS
14.2.1 GROWING NEED TO IMPROVE PROFITABILITY OF HEALTHCARE SERVICES TO DRIVE USE OF HCIT IN HOSPITALS
14.3 DIAGNOSTIC CENTERS
14.3.1 POPULARITY OF DIAGNOSTIC CENTERS TO PROPEL USE OF VNA AND PACS SOLUTIONS
14.4 AMBULATORY SURGERY CENTERS
14.4.1 INCREASING NUMBER OF INTERVENTIONAL IMAGING PROCEDURES TO SUPPORT USE OF VNA AND PACS SOLUTIONS IN AMBULATORY SURGERY CENTERS
14.5 OTHER END USERS
15 VENDOR NEUTRAL ARCHIVE (VNA) & PACS MARKET, BY REGION
15.1 INTRODUCTION
15.2 NORTH AMERICA
15.2.1 MACROECONOMIC OUTLOOK FOR NORTH AMERICA
15.2.2 US
15.2.2.1 Regulatory Interoperability Mandates and Cloud-First Enterprise Imaging Strategies
15.2.3 CANADA
15.2.3.1 Pan-Canadian Interoperability Drive Opens Enterprise Imaging Investment Pipeline
15.3 EUROPE
15.3.1 MACROECONOMIC OUTLOOK FOR EUROPE
15.3.2 GERMANY
15.3.2.1 Hospital Future Act Investment Cycle Accelerates PACS and VNA Modernization
15.3.3 UK
15.3.3.1 NHS Digital Diagnostic Programme and AI Mandate Catalyze GBP 700M Imaging IT Overhaul
15.3.4 FRANCE
15.3.4.1 S?gur du Num?rique Imaging Wave Drives RIS-PACS Interoperability at National Scale
15.3.5 ITALY
15.3.5.1 PNRR-Funded Hospital Modernization Drives PACS Replacement and Digital Imaging Upgrades
15.3.6 SPAIN
15.3.6.1 National Health System Digitization and Regional Imaging Network Expansion Drive Market Growth
15.3.7 REST OF EUROPE
15.4 ASIA PACIFIC
15.4.1 MACROECONOMIC OUTLOOK FOR ASIA PACIFIC
15.4.2 JAPAN
15.4.2.1 Aging Society and Society 5.0 Strategy Drive Next-Generation PACS Replacement Cycle
15.4.3 CHINA
15.4.3.1 Healthy China 2030 and 14th Five-Year Plan Drive National EMR and Imaging Informatization
15.4.4 INDIA
15.4.4.1 Ayushman Bharat Digital Mission Creates National Imaging Data Infrastructure Demand
15.4.5 REST OF ASIA PACIFIC
15.5 LATIN AMERICA
15.5.1 MACROECONOMIC OUTLOOK FOR LATIN AMERICA
15.5.2 BRAZIL
15.5.2.1 SUS Hospital Modernization and Private Sector AI Imaging Adoption Drive Regional Market Leadership
15.5.3 MEXICO
15.5.3.1 Private Hospital Expansion and Public Sector Technology Modernization Open PACS Growth Pathway
15.5.4 REST OF LATIN AMERICA
15.6 MIDDLE EAST & AFRICA
15.6.1 MACROECONOMIC OUTLOOK FOR MIDDLE EAST & AFRICA
15.6.2 GCC COUNTRIES
15.6.2.1 Vision 2030 and National Health Digitization Investments Accelerate Smart Hospital Imaging Deployments
15.6.3 REST OF MIDDLE EAST & AFRICA
16 COMPETITIVE LANDSCAPE
16.1 OVERVIEW
16.2 KEY PLAYERS’ STRATEGIES/RIGHT TO WIN
16.2.1 OVERVIEW OF STRATEGIES ADOPTED BY KEY PLAYERS IN VENDOR NEUTRAL ARCHIVE (VNA) & PACS MARKET
16.3 REVENUE SHARE ANALYSIS
16.4 MARKET SHARE ANALYSIS, 2025
16.5 COMPANY EVALUATION MATRIX: KEY PLAYERS, 2025
16.5.1 STARS
16.5.2 EMERGING LEADERS
16.5.3 PERVASIVE PLAYERS
16.5.4 PARTICIPANTS
16.5.5 COMPANY FOOTPRINT: KEY PLAYERS, 2025
16.5.5.1 Company footprint
16.5.5.2 Product footprint
16.5.5.3 Deployment footprint
16.5.5.4 End user footprint
16.5.5.5 Regional footprint
16.6 COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2025
16.6.1 PROGRESSIVE COMPANIES
16.6.2 RESPONSIVE COMPANIES
16.6.3 DYNAMIC COMPANIES
16.6.4 STARTING BLOCKS
16.6.5 COMPETITIVE BENCHMARKING: STARTUPS/SMES, 2025
16.6.5.1 Detailed list of key startups/SMEs
16.7 COMPANY VALUATION AND FINANCIAL METRICS
16.8 BRAND/SOFTWARE COMPARISON
16.9 COMPETITIVE SCENARIO
16.9.1 PRODUCT LAUNCHES & UPGRADES
16.9.2 DEALS
16.9.3 OTHER DEVELOPMENTS
17 COMPANY PROFILES
17.1 KEY COMPANIES
17.1.1 AGFA-GEVAERT GROUP
17.1.1.1 Business overview
17.1.1.2 Solutions offered
17.1.1.3 Recent developments
17.1.1.3.1 Deals
17.1.1.4 MnM view
17.1.1.4.1 Right to win
17.1.1.4.2 Strategic choices
17.1.1.4.3 Weaknesses & competitive threats
17.1.2 FUJIFILM HOLDINGS CORPORATION
17.1.2.1 Business overview
17.1.2.2 Solutions offered
17.1.2.3 Recent developments
17.1.2.3.1 Deals
17.1.2.3.2 Other developments
17.1.2.4 MnM view
17.1.2.4.1 Right to win
17.1.2.4.2 Strategic choices
17.1.2.4.3 Weaknesses & competitive threats
17.1.3 SECTRA AB
17.1.3.1 Business overview
17.1.3.2 Solutions offered
17.1.3.3 MnM view
17.1.3.3.1 Right to win
17.1.3.3.2 Strategic choices
17.1.3.3.3 Weaknesses & competitive threats
17.1.4 GE HEALTHCARE
17.1.4.1 Business overview
17.1.4.2 Solutions offered
17.1.4.3 Recent developments
17.1.4.3.1 Product launches
17.1.4.3.2 Deals
17.1.4.4 MnM view
17.1.4.4.1 Right to win
17.1.4.4.2 Strategic choices
17.1.4.4.3 Weaknesses & competitive threats
17.1.5 MERATIVE
17.1.5.1 Business overview
17.1.5.2 Solutions offered
17.1.5.3 Recent developments
17.1.5.3.1 Deals
17.1.5.4 MnM view
17.1.5.4.1 Key strengths
17.1.5.4.2 Strategic choices
17.1.5.4.3 Weaknesses & competitive threats
17.1.6 KONINKLIJKE PHILIPS N.V.
17.1.6.1 Business overview
17.1.6.2 Solutions offered
17.1.6.3 Recent developments
17.1.6.3.1 Product launches
17.1.6.3.2 Deals
17.1.7 CANON MEDICAL SYSTEMS CORPORATION
17.1.7.1 Business overview
17.1.7.2 Solutions offered
17.1.7.3 Recent developments
17.1.7.3.1 Deals
17.1.8 PAXERAHEALTH
17.1.8.1 Business overview
17.1.8.2 Solutions offered
17.1.9 NOVARAD CORPORATION
17.1.9.1 Business overview
17.1.9.2 Solutions offered
17.1.10 HYLAND SOFTWARE, INC.
17.1.10.1 Business overview
17.1.10.2 Solutions offered
17.1.10.3 Recent developments
17.1.10.3.1 Deals
17.1.11 SIEMENS HEALTHCARE LIMITED
17.1.11.1 Business overview
17.1.11.2 Solutions offered
17.1.11.3 Recent developments
17.1.11.3.1 Deals
17.1.12 BRIDGEHEAD SOFTWARE LTD.
17.1.12.1 Business overview
17.1.12.2 Solutions offered
17.1.13 CANOPY PARTNERS
17.1.13.1 Business overview
17.1.13.2 Solutions offered
17.1.14 CRELIOHEALTH INC.
17.1.14.1 Business overview
17.1.14.2 Solutions offered
17.1.15 ASPYRA, LLC
17.1.15.1 Business overview
17.1.15.2 Solutions offered
17.1.16 POSTDICOM
17.1.16.1 Business overview
17.1.16.2 Solutions offered
17.1.17 MEDICASOFT
17.1.17.1 Business overview
17.1.17.2 Solutions offered
17.1.18 ESAOTE SPA
17.1.18.1 Business overview
17.1.18.2 Solutions offered
17.1.18.3 Recent developments
17.1.18.3.1 Product launches
17.1.19 VISUS HEALTH IT GMBH
17.1.19.1 Business overview
17.1.19.2 Solutions offered
17.2 OTHER PLAYERS
17.2.1 ADVAHEALTH SOLUTIONS
17.2.2 SOFTTEAM SOLUTIONS PVT. LTD.
17.2.3 ARO SYSTEMS
17.2.4 CENTRAL DATA NETWORKS
17.2.5 ONEPACS
17.2.6 DEDALUS SPA.
18 RESEARCH METHODOLOGY
18.1 RESEARCH APPROACH
18.1.1 SECONDARY RESEARCH
18.1.1.1 Key data from secondary sources
18.1.2 PRIMARY RESEARCH
18.1.2.1 Primary sources
18.1.2.2 Key data from primary sources
18.1.2.3 Breakdown of primary interviews
18.1.2.4 Insights from primary experts
18.2 RESEARCH METHODOLOGY DESIGN
18.3 MARKET SIZE ESTIMATION
18.4 DATA TRIANGULATION
18.5 RESEARCH ASSUMPTIONS
18.6 RESEARCH LIMITATIONS
18.6.1 METHODOLOGY-RELATED
18.6.2 SCOPE-RELATED
18.7 RISK ASSESSMENT
19 APPENDIX
19.1 DISCUSSION GUIDE
19.2 KNOWLEDGESTORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL
19.3 CUSTOMIZATION OPTIONS
19.4 RELATED REPORTS
19.5 AUTHOR DETAILS
1.1 STUDY OBJECTIVES
1.2 MARKET DEFINITION
1.3 STUDY SCOPE
1.3.1 MARKET SEGMENTATION AND REGIONAL SCOPE
1.3.2 INCLUSIONS AND EXCLUSIONS
1.3.3 YEARS CONSIDERED
1.4 CURRENCY CONSIDERED
1.5 STAKEHOLDERS
2 EXECUTIVE SUMMARY
2.1 KEY INSIGHTS AND MARKET HIGHLIGHTS
2.2 KEY MARKET PARTICIPANTS: MAPPING OF STRATEGIC DEVELOPMENTS
2.3 DISRUPTIVE TRENDS SHAPING VNA & PACS MARKET
2.4 HIGH-GROWTH SEGMENTS
2.5 REGIONAL SNAPSHOT: MARKET SIZE, GROWTH RATE, AND FORECAST
3 PREMIUM INSIGHTS
3.1 ATTRACTIVE OPPORTUNITIES FOR VENDOR NEUTRAL ARCHIVE (VNA) & PACS MARKET
3.2 NORTH AMERICA VNA PACS MARKET, BY END USER AND COUNTRY
3.3 VENDOR NEUTRAL ARCHIVE (VNA) & PACS MARKET, BY COUNTRY
4 MARKET OVERVIEW
4.1 INTRODUCTION
4.2 MARKET DYNAMICS
4.2.1 DRIVERS
4.2.1.1 Heightened investments in medical imaging technologies
4.2.1.2 Growing demand for streamlined healthcare data management solutions
4.2.1.3 Integration of PACS/VNA with Electronic Medical Records (EMRs)
4.2.2 RESTRAINTS
4.2.2.1 High initial investment
4.2.2.2 Lack of standardized protocols and interoperability frameworks
4.2.3 OPPORTUNITIES
4.2.3.1 Government initiatives to increase penetration of AI in medical imaging
4.2.3.2 Increasing medical imaging procedures and large imaging data silos
4.2.3.3 Rapid uptake of big data in healthcare
4.2.4 CHALLENGES
4.2.4.1 Rising security concerns related to cloud-based image processing and analytics
4.2.4.2 Data security issues
4.3 UNMET NEEDS AND WHITE SPACES
4.4 INTERCONNECTED MARKETS AND CROSS-SECTOR OPPORTUNITIES
4.5 STRATEGIC MOVES BY TIER-1/2/3 PLAYERS
5 INDUSTRY TRENDS
5.1 PORTER’S FIVE FORCES ANALYSIS
5.1.1 INTENSITY OF COMPETITIVE RIVALRY
5.1.2 BARGAINING POWER OF SUPPLIERS
5.1.3 BARGAINING POWER OF BUYERS
5.1.4 THREAT OF NEW ENTRANTS
5.1.5 THREAT OF SUBSTITUTES
5.2 MACROECONOMICS INDICATORS
5.2.1 INTRODUCTION
5.2.2 GDP TRENDS AND FORECAST
5.2.3 TRENDS IN GLOBAL HEALTHCARE IT INDUSTRY
5.3 VALUE CHAIN ANALYSIS
5.4 ECOSYSTEM MAPPING
5.5 PRICING ANALYSIS
5.5.1 AVERAGE SELLING PRICE (ASP) TREND OF VNA AND PACS SOLUTIONS, BY PRODUCT TYPE
5.5.2 AVERAGE SELLING PRICE TREND, BY REGION
5.6 KEY CONFERENCES AND EVENTS, 2026–2027
5.7 TRENDS/DISRUPTIONS IMPACTING CUSTOMER BUSINESS
5.8 INVESTMENT AND FUNDING SCENARIO
5.9 CASE STUDY ANALYSIS
5.9.1 AMBRA HEALTH UTILIZED AWS CLOUD SERVICES TO PROPEL WORLDWIDE GROWTH OF ITS MEDICAL IMAGING PLATFORM
5.9.2 NHS TRUST ADOPTED INTEGRATION AND INSTANT DATA ACCESS OFFERED BY SYNAPPS VNA TO ESTABLISH UNIFIED PLATFORM FOR STORING AND MANAGING DICOM IMAGE DATA
5.10 IMPACT OF 2025 US TARIFF OVERVIEW
5.10.1 INTRODUCTION
5.10.2 KEY TARIFF RATES
5.10.3 PRICE IMPACT ANALYSIS
5.11 IMPACT ON COUNTRY/REGION
5.11.1 THE US
5.11.2 EUROPE
5.11.3 APAC
5.12 IMPACT ON END USE INDUSTRIES
5.13 CONCLUSION
6 TECHNOLOGICAL ADVANCEMENTS, AI-DRIVEN IMPACT, PATENTS, INNOVATIONS, AND FUTURE APPLICATIONS
6.1 KEY EMERGING TECHNOLOGIES
6.1.1 DICOM (DIGITAL IMAGING AND COMMUNICATIONS IN MEDICINE)
6.1.2 ENTERPRISE IMAGING SOLUTIONS
6.1.3 CLOUD-BASED STORAGE AND SERVICES
6.2 COMPLEMENTARY TECHNOLOGIES
6.2.1 IMAGE EXCHANGE NETWORKS
6.2.2 DATA ANALYTICS AND BUSINESS INTELLIGENCE
6.3 ADJACENT TECHNOLOGIES
6.3.1 HEALTH INFORMATION EXCHANGE (HIE)
6.4 PATENT ANALYSIS
6.4.1 INSIGHTS: JURISDICTION AND TOP APPLICANT ANALYSIS
6.5 FUTURE APPLICATIONS
6.5.1 AI-ENABLED ENTERPRISE DIAGNOSTIC ORCHESTRATION
6.5.2 MULTI-SPECIALTY ENTERPRISE IMAGING REPOSITORY
6.5.3 IMAGING DATA LAKE FOR CLINICAL RESEARCH AND REAL-WORLD EVIDENCE
6.5.4 CLOUD-BASED REGIONAL IMAGE EXCHANGE AND VIRTUAL CARE NETWORKS
6.5.5 PERSONALIZED AND LONGITUDINAL IMAGING INTELLIGENCE
7 REGULATORY LANDSCAPE
7.1 REGIONAL REGULATIONS AND COMPLIANCE
7.1.1 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
7.1.2 REGULATIONS
7.1.2.1 US
7.1.2.2 Europe
7.1.2.3 China
7.1.2.4 Japan
7.1.2.5 India
7.1.3 INDUSTRY STANDARDS
8 CUSTOMER LANDSCAPE & BUYER BEHAVIOR
8.1 INTRODUCTION
8.2 DECISION-MAKING PROCESS
8.3 BUYER STAKEHOLDERS AND BUYING EVALUATION CRITERIA
8.3.1 KEY STAKEHOLDERS IN BUYING PROCESS
8.3.2 BUYING CRITERIA
8.4 ADOPTION BARRIERS & INTERNAL CHALLENGES
8.5 UNMET NEEDS FROM VARIOUS END-USE INDUSTRIES
8.5.1 UNMET NEEDS
8.5.2 END-USER EXPECTATIONS
8.6 MARKET PROFITABILITY
9 VENDOR NEUTRAL ARCHIVE (VNA) & PACS MARKET, BY PRODUCT TYPE
9.1 INTRODUCTION
9.2 VNA
9.2.1 DEPARTMENT VNA
9.2.1.1 Phased imaging modernization driving VNA adoption and interoperability growth
9.2.2 MULTI-DEPARTMENT VNA
9.2.2.1 Cross-department imaging consolidation driving scalable enterprise data platform adoption
9.2.3 MULTI-SITE VNA
9.2.3.1 Cloud-based multi-site imaging consolidation enabling scalable, centralized care delivery
9.3 PACS
9.3.1 DEPARTMENT PACS
9.3.1.1 Rising imaging volumes and workforce shortages driving workflow-centric PACS adoption
9.3.2 MULTI-DEPARTMENT PACS
9.3.2.1 Shared imaging platforms reducing silos and enabling cross-specialty collaboration
9.3.3 MULTI-SITE PACS
9.3.3.1 Centralized cloud PACS enabling cross-site workload balancing and productivity gains
10 VENDOR NEUTRAL ARCHIVE (VNA) & PACS MARKET, BY MODALITY
10.1 INTRODUCTION
10.2 CT
10.2.1 RAPID RISE IN NEED FOR CT EXAMINATIONS TO SUPPORT MARKET GROWTH
10.3 MAMMOGRAPHY
10.3.1 RISE IN NUMBER OF MAMMOGRAPHY PROCEDURES TO DRIVE MARKET GROWTH
10.4 ULTRASOUND
10.4.1 RISING TECHNOLOGICAL ADVANCEMENT IN ULTRASOUND DEVICES TO SUPPORT MARKET GROWTH
10.5 MAGNETIC RESONANCE IMAGING (MRI)
10.5.1 MRI IS COST-EFFECTIVE AND EASILY AVAILABLE COMPARED TO PET
10.6 X-RAY
10.6.1 RAPID ADOPTION OF X-RAY IMAGING COMPARED TO OTHER MODALITIES TO BOOST MARKET
10.7 PET
10.7.1 INCREASING USE OF NUCLEAR MEDICINES TO SUPPORT POPULARITY OF PET
11 VENDOR NEUTRAL ARCHIVE (VNA) & PACS MARKET, BY DEPLOYMENT MODEL
11.1 INTRODUCTION
11.2 ON-PREMISE MODEL
11.2.1 ON-PREMISE DEPLOYMENT MODEL PROVIDES HEALTHCARE ORGANIZATIONS WITH GREAT CONTROL AND SECURITY OVER SENSITIVE PATIENT DATA
11.3 CLOUD-BASED MODEL
11.3.1 TECHNOLOGICAL ADVANCEMENTS IN DIAGNOSTIC IMAGING MODALITIES TO DRIVE CLOUD-BASED MODEL’S POPULARITY
11.4 HYBRID MODEL
11.4.1 UNIFIED EFFICIENCY FOR OPTIMAL PERFORMANCE TO DRIVE HYBRID VNA AND PACS SOLUTIONS
12 VENDOR NEUTRAL ARCHIVE (VNA) & PACS MARKET, BY VENDOR TYPE
12.1 INTRODUCTION
12.2 INDEPENDENT VENDOR
12.2.1 DOMINANCE OF INDEPENDENT VENDORS TO CAPTURE SIGNIFICANT MARKET SHARE
12.3 THIRD-PARTY VENDOR
12.3.1 NEED FOR INNOVATIVE SOLUTIONS TO FUEL SURGE IN THIRD-PARTY VENDORS’ PRESENCE IN MARKET
13 VENDOR NEUTRAL ARCHIVE (VNA) & PACS MARKET, BY APPLICATION
13.1 INTRODUCTION
13.2 CARDIOLOGY
13.2.1 RISING CASES OF CARDIAC DISORDERS TO DRIVE MARKET
13.3 ORTHOPEDIC
13.3.1 GROWTH IN CASES OF ARTHRITIS TO SUPPORT MARKET GROWTH
13.4 ONCOLOGY
13.4.1 RISE IN NUMBER OF CANCER CASES TO DRIVE USE OF VNA AND PACS SOLUTIONS FOR ONCOLOGY
13.5 NEUROLOGY
13.5.1 INCREASING DEMAND FOR ADVANCED NEUROLOGICAL IMAGING TECHNOLOGIES TO SPUR GROWTH
13.6 OBSTETRICS & GYNECOLOGY
13.6.1 USE OF 3D AND 4D IMAGING FOR MONITORING FETUS GROWTH AND DIAGNOSING HIGH-RISK PREGNANCIES TO DRIVE APPLICATION OF VNA AND PACS SOLUTIONS
13.7 OTHER APPLICATIONS
14 VENDOR NEUTRAL ARCHIVE (VNA) & PACS MARKET, BY END USER
14.1 INTRODUCTION
14.2 HOSPITALS & CLINICS
14.2.1 GROWING NEED TO IMPROVE PROFITABILITY OF HEALTHCARE SERVICES TO DRIVE USE OF HCIT IN HOSPITALS
14.3 DIAGNOSTIC CENTERS
14.3.1 POPULARITY OF DIAGNOSTIC CENTERS TO PROPEL USE OF VNA AND PACS SOLUTIONS
14.4 AMBULATORY SURGERY CENTERS
14.4.1 INCREASING NUMBER OF INTERVENTIONAL IMAGING PROCEDURES TO SUPPORT USE OF VNA AND PACS SOLUTIONS IN AMBULATORY SURGERY CENTERS
14.5 OTHER END USERS
15 VENDOR NEUTRAL ARCHIVE (VNA) & PACS MARKET, BY REGION
15.1 INTRODUCTION
15.2 NORTH AMERICA
15.2.1 MACROECONOMIC OUTLOOK FOR NORTH AMERICA
15.2.2 US
15.2.2.1 Regulatory Interoperability Mandates and Cloud-First Enterprise Imaging Strategies
15.2.3 CANADA
15.2.3.1 Pan-Canadian Interoperability Drive Opens Enterprise Imaging Investment Pipeline
15.3 EUROPE
15.3.1 MACROECONOMIC OUTLOOK FOR EUROPE
15.3.2 GERMANY
15.3.2.1 Hospital Future Act Investment Cycle Accelerates PACS and VNA Modernization
15.3.3 UK
15.3.3.1 NHS Digital Diagnostic Programme and AI Mandate Catalyze GBP 700M Imaging IT Overhaul
15.3.4 FRANCE
15.3.4.1 S?gur du Num?rique Imaging Wave Drives RIS-PACS Interoperability at National Scale
15.3.5 ITALY
15.3.5.1 PNRR-Funded Hospital Modernization Drives PACS Replacement and Digital Imaging Upgrades
15.3.6 SPAIN
15.3.6.1 National Health System Digitization and Regional Imaging Network Expansion Drive Market Growth
15.3.7 REST OF EUROPE
15.4 ASIA PACIFIC
15.4.1 MACROECONOMIC OUTLOOK FOR ASIA PACIFIC
15.4.2 JAPAN
15.4.2.1 Aging Society and Society 5.0 Strategy Drive Next-Generation PACS Replacement Cycle
15.4.3 CHINA
15.4.3.1 Healthy China 2030 and 14th Five-Year Plan Drive National EMR and Imaging Informatization
15.4.4 INDIA
15.4.4.1 Ayushman Bharat Digital Mission Creates National Imaging Data Infrastructure Demand
15.4.5 REST OF ASIA PACIFIC
15.5 LATIN AMERICA
15.5.1 MACROECONOMIC OUTLOOK FOR LATIN AMERICA
15.5.2 BRAZIL
15.5.2.1 SUS Hospital Modernization and Private Sector AI Imaging Adoption Drive Regional Market Leadership
15.5.3 MEXICO
15.5.3.1 Private Hospital Expansion and Public Sector Technology Modernization Open PACS Growth Pathway
15.5.4 REST OF LATIN AMERICA
15.6 MIDDLE EAST & AFRICA
15.6.1 MACROECONOMIC OUTLOOK FOR MIDDLE EAST & AFRICA
15.6.2 GCC COUNTRIES
15.6.2.1 Vision 2030 and National Health Digitization Investments Accelerate Smart Hospital Imaging Deployments
15.6.3 REST OF MIDDLE EAST & AFRICA
16 COMPETITIVE LANDSCAPE
16.1 OVERVIEW
16.2 KEY PLAYERS’ STRATEGIES/RIGHT TO WIN
16.2.1 OVERVIEW OF STRATEGIES ADOPTED BY KEY PLAYERS IN VENDOR NEUTRAL ARCHIVE (VNA) & PACS MARKET
16.3 REVENUE SHARE ANALYSIS
16.4 MARKET SHARE ANALYSIS, 2025
16.5 COMPANY EVALUATION MATRIX: KEY PLAYERS, 2025
16.5.1 STARS
16.5.2 EMERGING LEADERS
16.5.3 PERVASIVE PLAYERS
16.5.4 PARTICIPANTS
16.5.5 COMPANY FOOTPRINT: KEY PLAYERS, 2025
16.5.5.1 Company footprint
16.5.5.2 Product footprint
16.5.5.3 Deployment footprint
16.5.5.4 End user footprint
16.5.5.5 Regional footprint
16.6 COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2025
16.6.1 PROGRESSIVE COMPANIES
16.6.2 RESPONSIVE COMPANIES
16.6.3 DYNAMIC COMPANIES
16.6.4 STARTING BLOCKS
16.6.5 COMPETITIVE BENCHMARKING: STARTUPS/SMES, 2025
16.6.5.1 Detailed list of key startups/SMEs
16.7 COMPANY VALUATION AND FINANCIAL METRICS
16.8 BRAND/SOFTWARE COMPARISON
16.9 COMPETITIVE SCENARIO
16.9.1 PRODUCT LAUNCHES & UPGRADES
16.9.2 DEALS
16.9.3 OTHER DEVELOPMENTS
17 COMPANY PROFILES
17.1 KEY COMPANIES
17.1.1 AGFA-GEVAERT GROUP
17.1.1.1 Business overview
17.1.1.2 Solutions offered
17.1.1.3 Recent developments
17.1.1.3.1 Deals
17.1.1.4 MnM view
17.1.1.4.1 Right to win
17.1.1.4.2 Strategic choices
17.1.1.4.3 Weaknesses & competitive threats
17.1.2 FUJIFILM HOLDINGS CORPORATION
17.1.2.1 Business overview
17.1.2.2 Solutions offered
17.1.2.3 Recent developments
17.1.2.3.1 Deals
17.1.2.3.2 Other developments
17.1.2.4 MnM view
17.1.2.4.1 Right to win
17.1.2.4.2 Strategic choices
17.1.2.4.3 Weaknesses & competitive threats
17.1.3 SECTRA AB
17.1.3.1 Business overview
17.1.3.2 Solutions offered
17.1.3.3 MnM view
17.1.3.3.1 Right to win
17.1.3.3.2 Strategic choices
17.1.3.3.3 Weaknesses & competitive threats
17.1.4 GE HEALTHCARE
17.1.4.1 Business overview
17.1.4.2 Solutions offered
17.1.4.3 Recent developments
17.1.4.3.1 Product launches
17.1.4.3.2 Deals
17.1.4.4 MnM view
17.1.4.4.1 Right to win
17.1.4.4.2 Strategic choices
17.1.4.4.3 Weaknesses & competitive threats
17.1.5 MERATIVE
17.1.5.1 Business overview
17.1.5.2 Solutions offered
17.1.5.3 Recent developments
17.1.5.3.1 Deals
17.1.5.4 MnM view
17.1.5.4.1 Key strengths
17.1.5.4.2 Strategic choices
17.1.5.4.3 Weaknesses & competitive threats
17.1.6 KONINKLIJKE PHILIPS N.V.
17.1.6.1 Business overview
17.1.6.2 Solutions offered
17.1.6.3 Recent developments
17.1.6.3.1 Product launches
17.1.6.3.2 Deals
17.1.7 CANON MEDICAL SYSTEMS CORPORATION
17.1.7.1 Business overview
17.1.7.2 Solutions offered
17.1.7.3 Recent developments
17.1.7.3.1 Deals
17.1.8 PAXERAHEALTH
17.1.8.1 Business overview
17.1.8.2 Solutions offered
17.1.9 NOVARAD CORPORATION
17.1.9.1 Business overview
17.1.9.2 Solutions offered
17.1.10 HYLAND SOFTWARE, INC.
17.1.10.1 Business overview
17.1.10.2 Solutions offered
17.1.10.3 Recent developments
17.1.10.3.1 Deals
17.1.11 SIEMENS HEALTHCARE LIMITED
17.1.11.1 Business overview
17.1.11.2 Solutions offered
17.1.11.3 Recent developments
17.1.11.3.1 Deals
17.1.12 BRIDGEHEAD SOFTWARE LTD.
17.1.12.1 Business overview
17.1.12.2 Solutions offered
17.1.13 CANOPY PARTNERS
17.1.13.1 Business overview
17.1.13.2 Solutions offered
17.1.14 CRELIOHEALTH INC.
17.1.14.1 Business overview
17.1.14.2 Solutions offered
17.1.15 ASPYRA, LLC
17.1.15.1 Business overview
17.1.15.2 Solutions offered
17.1.16 POSTDICOM
17.1.16.1 Business overview
17.1.16.2 Solutions offered
17.1.17 MEDICASOFT
17.1.17.1 Business overview
17.1.17.2 Solutions offered
17.1.18 ESAOTE SPA
17.1.18.1 Business overview
17.1.18.2 Solutions offered
17.1.18.3 Recent developments
17.1.18.3.1 Product launches
17.1.19 VISUS HEALTH IT GMBH
17.1.19.1 Business overview
17.1.19.2 Solutions offered
17.2 OTHER PLAYERS
17.2.1 ADVAHEALTH SOLUTIONS
17.2.2 SOFTTEAM SOLUTIONS PVT. LTD.
17.2.3 ARO SYSTEMS
17.2.4 CENTRAL DATA NETWORKS
17.2.5 ONEPACS
17.2.6 DEDALUS SPA.
18 RESEARCH METHODOLOGY
18.1 RESEARCH APPROACH
18.1.1 SECONDARY RESEARCH
18.1.1.1 Key data from secondary sources
18.1.2 PRIMARY RESEARCH
18.1.2.1 Primary sources
18.1.2.2 Key data from primary sources
18.1.2.3 Breakdown of primary interviews
18.1.2.4 Insights from primary experts
18.2 RESEARCH METHODOLOGY DESIGN
18.3 MARKET SIZE ESTIMATION
18.4 DATA TRIANGULATION
18.5 RESEARCH ASSUMPTIONS
18.6 RESEARCH LIMITATIONS
18.6.1 METHODOLOGY-RELATED
18.6.2 SCOPE-RELATED
18.7 RISK ASSESSMENT
19 APPENDIX
19.1 DISCUSSION GUIDE
19.2 KNOWLEDGESTORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL
19.3 CUSTOMIZATION OPTIONS
19.4 RELATED REPORTS
19.5 AUTHOR DETAILS
LIST OF TABLES
TABLE 1 EXCHANGE RATES UTILIZED FOR CONVERSION TO USD
TABLE 2 IMPACT OF PORTER’S FIVE FORCES ON VENDOR NEUTRAL ARCHIVE (VNA) & PACS MARKET
TABLE 3 VENDOR NEUTRAL ARCHIVE (VNA) & PACS MARKET: ROLE IN ECOSYSTEM
TABLE 4 AVERAGE SELLING PRICE OF PACS SOLUTIONS, BY PRODUCT TYPE (USD)
TABLE 5 AVERAGE SELLING PRICE OF VNA SOLUTIONS, BY PRODUCT TYPE (USD)
TABLE 6 KEY CONFERENCES AND EVENTS, 2026–2027
TABLE 7 JURISDICTION ANALYSIS OF TOP APPLICANT COUNTRIES FOR AI IN TELEHEALTH & TELEMEDICINE
TABLE 8 LIST OF PATENTS/PATENT APPLICATIONS, 2015–2025
TABLE 9 NORTH AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
TABLE 10 EUROPE: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
TABLE 11 ASIA PACIFIC: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
TABLE 12 ROW: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
TABLE 13 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS OF FOUR END USERS
TABLE 14 KEY BUYING CRITERIA FOR FOUR END USERS
TABLE 15 UNMET NEEDS IN VENDOR NEUTRAL ARCHIVE (VNA) & PACS MARKET
TABLE 16 END-USER EXPECTATIONS IN VENDOR NEUTRAL ARCHIVE (VNA) & PACS MARKET
TABLE 17 VENDOR NEUTRAL ARCHIVE (VNA) & PACS MARKET, BY PRODUCT TYPE, 2024–2031 (USD MILLION)
TABLE 18 VENDOR NEUTRAL ARCHIVE (VNA) MARKET, BY PRODUCT TYPE, 2024–2031 (USD MILLION)
TABLE 19 VENDOR NEUTRAL ARCHIVE (VNA) MARKET, BY COUNTRY/REGION, 2024–2031 (USD MILLION)
TABLE 20 DEPARTMENT VENDOR NEUTRAL ARCHIVE (VNA) MARKET, BY COUNTRY/REGION, 2024–2031 (USD MILLION)
TABLE 21 MULTI-DEPARTMENT VENDOR NEUTRAL ARCHIVE (VNA) MARKET, BY COUNTRY/REGION, 2024–2031 (USD MILLION)
TABLE 22 MULTI-SITE VENDOR NEUTRAL ARCHIVE (VNA) MARKET, BY COUNTRY/REGION, 2024–2031 (USD MILLION)
TABLE 23 PACS MARKET, BY PRODUCT TYPE, 2024–2031 (USD MILLION)
TABLE 24 PACS MARKET, BY COUNTRY/REGION, 2024–2031 (USD MILLION)
TABLE 25 DEPARTMENT PACS MARKET, BY COUNTRY/REGION, 2024–2031 (USD MILLION)
TABLE 26 MULTI-DEPARTMENT PACS MARKET, BY COUNTRY/REGION, 2024–2031 (USD MILLION)
TABLE 27 MULTI-SITE PACS MARKET, BY COUNTRY/REGION, 2024–2031 (USD MILLION)
TABLE 28 VENDOR NEUTRAL ARCHIVE (VNA) & PACS MARKET, BY MODALITY, 2024–2031 (USD MILLION)
TABLE 29 VENDOR NEUTRAL ARCHIVE (VNA) & PACS MARKET FOR CT, BY COUNTRY/REGION, 2024–2031 (USD MILLION)
TABLE 30 VENDOR NEUTRAL ARCHIVE (VNA) & PACS MARKET FOR MAMMOGRAPHY, BY COUNTRY/REGION, 2024–2031 (USD MILLION)
TABLE 31 VENDOR NEUTRAL ARCHIVE (VNA) & PACS MARKET FOR ULTRASOUND, BY COUNTRY/REGION, 2024–2031 (USD MILLION)
TABLE 32 VENDOR NEUTRAL ARCHIVE (VNA) & PACS MARKET FOR MAGNETIC RESONANCE IMAGING (MRI), BY COUNTRY/REGION, 2024–2031 (USD MILLION)
TABLE 33 VENDOR NEUTRAL ARCHIVE (VNA) & PACS MARKET FOR X-RAY, BY COUNTRY/REGION, 2024–2031 (USD MILLION)
TABLE 34 VENDOR NEUTRAL ARCHIVE (VNA) & PACS MARKET FOR PET, BY COUNTRY/REGION, 2024–2031 (USD MILLION)
TABLE 35 VENDOR NEUTRAL ARCHIVE (VNA) & PACS MARKET, BY DEPLOYMENT MODEL, 2024–2031 (USD MILLION)
TABLE 36 ON-PREMISE VENDOR NEUTRAL ARCHIVE (VNA) & PACS MARKET, BY COUNTRY/REGION, 2024–2031 (USD MILLION)
TABLE 37 CLOUD-BASED VENDOR NEUTRAL ARCHIVE (VNA) & PACS MARKET, BY COUNTRY/REGION, 2024–2031 (USD MILLION)
TABLE 38 HYBRID VENDOR NEUTRAL ARCHIVE (VNA) & PACS MARKET, BY COUNTRY/REGION, 2024–2031 (USD MILLION)
TABLE 39 VENDOR NEUTRAL ARCHIVE (VNA) & PACS MARKET, BY VENDOR TYPE, 2024–2031 (USD MILLION)
TABLE 40 INDEPENDENT VENDOR NEUTRAL ARCHIVE (VNA) & PACS MARKET, BY COUNTRY/REGION, 2024–2031 (USD MILLION)
TABLE 41 THIRD-PARTY VENDOR NEUTRAL ARCHIVE (VNA) & PACS MARKET, BY COUNTRY/REGION, 2024–2031 (USD MILLION)
TABLE 42 VENDOR NEUTRAL ARCHIVE (VNA) & PACS MARKET, BY APPLICATION, 2024–2031 (USD MILLION)
TABLE 43 VENDOR NEUTRAL ARCHIVE (VNA) & PACS MARKET FOR CARDIOLOGY APPLICATIONS, BY COUNTRY/REGION, 2024–2031 (USD MILLION)
TABLE 44 VENDOR NEUTRAL ARCHIVE (VNA) & PACS MARKET FOR ORTHOPEDIC APPLICATIONS, BY COUNTRY/REGION, 2024–2031 (USD MILLION)
TABLE 45 VENDOR NEUTRAL ARCHIVE (VNA) & PACS MARKET FOR ONCOLOGY APPLICATIONS, BY COUNTRY/REGION, 2024–2031 (USD MILLION)
TABLE 46 VENDOR NEUTRAL ARCHIVE (VNA) & PACS MARKET FOR NEUROLOGY APPLICATIONS, BY COUNTRY/REGION, 2024–2031 (USD MILLION)
TABLE 47 VENDOR NEUTRAL ARCHIVE (VNA) & PACS MARKET FOR OBSTETRICS AND GYNECOLOGY APPLICATIONS, BY COUNTRY/REGION, 2024–2031 (USD MILLION)
TABLE 48 VENDOR NEUTRAL ARCHIVE (VNA) & PACS MARKET FOR OTHER APPLICATIONS, BY COUNTRY/REGION, 2024–2031 (USD MILLION)
TABLE 49 VENDOR NEUTRAL ARCHIVE (VNA) & PACS MARKET, BY END USER, 2024–2031 (USD MILLION)
TABLE 50 VENDOR NEUTRAL ARCHIVE (VNA) & PACS MARKET FOR HOSPITALS & CLINICS, BY COUNTRY/REGION, 2024–2031 (USD MILLION)
TABLE 51 VENDOR NEUTRAL ARCHIVE (VNA) & PACS MARKET FOR DIAGNOSTIC CENTERS, BY COUNTRY/REGION, 2024–2031 (USD MILLION)
TABLE 52 VENDOR NEUTRAL ARCHIVE (VNA) & PACS MARKET FOR AMBULATORY SURGICAL CENTERS, BY COUNTRY/REGION, 2024–2031 (USD MILLION)
TABLE 53 VENDOR NEUTRAL ARCHIVE (VNA) & PACS MARKET FOR OTHER END USERS, BY COUNTRY/REGION, 2024–2031 (USD MILLION)
TABLE 54 VENDOR NEUTRAL ARCHIVE (VNA) & PACS MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 55 NORTH AMERICA: VENDOR NEUTRAL ARCHIVE (VNA) & PACS MARKET, BY COUNTRY/REGION, 2024–2031 (USD MILLION)
TABLE 56 NORTH AMERICA: VENDOR NEUTRAL ARCHIVE (VNA) & PACS MARKET, BY PRODUCT TYPE, 2024–2031 (USD MILLION)
TABLE 57 NORTH AMERICA: VENDOR NEUTRAL ARCHIVE (VNA) MARKET, BY PRODUCT TYPE, 2024–2031 (USD MILLION)
TABLE 58 NORTH AMERICA: PACS MARKET, BY PRODUCT TYPE, 2024–2031 (USD MILLION)
TABLE 59 NORTH AMERICA: VENDOR NEUTRAL ARCHIVE (VNA) & PACS MARKET, BY MODALITY, 2024–2031 (USD MILLION)
TABLE 60 NORTH AMERICA: VENDOR NEUTRAL ARCHIVE (VNA) & PACS MARKET, BY DEPLOYMENT MODEL, 2024–2031 (USD MILLION)
TABLE 61 NORTH AMERICA: VENDOR NEUTRAL ARCHIVE (VNA) & PACS MARKET, BY VENDOR TYPE, 2024–2031 (USD MILLION)
TABLE 62 NORTH AMERICA: VENDOR NEUTRAL ARCHIVE (VNA) & PACS MARKET, BY APPLICATION, 2024–2031 (USD MILLION)
TABLE 63 NORTH AMERICA: VENDOR NEUTRAL ARCHIVE (VNA) & PACS MARKET, BY END USER, 2024–2031 (USD MILLION)
TABLE 64 US: KEY MACRO INDICATORS
TABLE 65 US: VENDOR NEUTRAL ARCHIVE (VNA) & PACS MARKET, BY PRODUCT TYPE, 2024–2031 (USD MILLION)
TABLE 66 US: VENDOR NEUTRAL ARCHIVE (VNA) MARKET, BY PRODUCT TYPE, 2024–2031 (USD MILLION)
TABLE 67 US: PACS MARKET, BY PRODUCT TYPE, 2024–2031 (USD MILLION)
TABLE 68 US: VENDOR NEUTRAL ARCHIVE (VNA) & PACS MARKET, BY MODALITY, 2024–2031 (USD MILLION)
TABLE 69 US: VENDOR NEUTRAL ARCHIVE (VNA) & PACS MARKET, BY DEPLOYMENT MODEL, 2024–2031 (USD MILLION)
TABLE 70 US: VENDOR NEUTRAL ARCHIVE (VNA) & PACS MARKET, BY VENDOR TYPE, 2024–2031 (USD MILLION)
TABLE 71 US: VENDOR NEUTRAL ARCHIVE (VNA) & PACS MARKET, BY APPLICATION, 2024–2031 (USD MILLION)
TABLE 72 US: VENDOR NEUTRAL ARCHIVE (VNA) & PACS MARKET, BY END USER, 2024–2031 (USD MILLION)
TABLE 73 CANADA: VENDOR NEUTRAL ARCHIVE (VNA) & PACS MARKET, BY PRODUCT TYPE, 2024–2031 (USD MILLION)
TABLE 74 CANADA: VENDOR NEUTRAL ARCHIVE (VNA) MARKET, BY PRODUCT TYPE, 2024–2031 (USD MILLION)
TABLE 75 CANADA: PACS MARKET, BY PRODUCT TYPE, 2024–2031 (USD MILLION)
TABLE 76 CANADA: VENDOR NEUTRAL ARCHIVE (VNA) & PACS MARKET, BY MODALITY, 2024–2031 (USD MILLION)
TABLE 77 CANADA: VENDOR NEUTRAL ARCHIVE (VNA) & PACS MARKET, BY DEPLOYMENT MODEL, 2024–2031 (USD MILLION)
TABLE 78 CANADA: VENDOR NEUTRAL ARCHIVE (VNA) & PACS MARKET, BY VENDOR TYPE, 2024–2031 (USD MILLION)
TABLE 79 CANADA: VENDOR NEUTRAL ARCHIVE (VNA) & PACS MARKET, BY APPLICATION, 2024–2031 (USD MILLION)
TABLE 80 CANADA: VENDOR NEUTRAL ARCHIVE (VNA) & PACS MARKET, BY END USER, 2024–2031 (USD MILLION)
TABLE 81 EUROPE: VENDOR NEUTRAL ARCHIVE (VNA) & PACS MARKET, BY COUNTRY/REGION, 2024–2031 (USD MILLION)
TABLE 82 EUROPE: VENDOR NEUTRAL ARCHIVE (VNA) & PACS MARKET, BY PRODUCT TYPE, 2024–2031 (USD MILLION)
TABLE 83 EUROPE: VENDOR NEUTRAL ARCHIVE (VNA) MARKET, BY PRODUCT TYPE, 2024–2031 (USD MILLION)
TABLE 84 EUROPE: PACS MARKET, BY PRODUCT TYPE, 2024–2031 (USD MILLION)
TABLE 85 EUROPE: VENDOR NEUTRAL ARCHIVE (VNA) & PACS MARKET, BY MODALITY, 2024–2031 (USD MILLION)
TABLE 86 EUROPE: VENDOR NEUTRAL ARCHIVE (VNA) & PACS MARKET, BY DEPLOYMENT MODEL, 2024–2031 (USD MILLION)
TABLE 87 EUROPE: VENDOR NEUTRAL ARCHIVE (VNA) & PACS MARKET, BY VENDOR TYPE, 2024–2031 (USD MILLION)
TABLE 88 EUROPE: VENDOR NEUTRAL ARCHIVE (VNA) & PACS MARKET, BY APPLICATION, 2024–2031 (USD MILLION)
TABLE 89 EUROPE: VENDOR NEUTRAL ARCHIVE (VNA) & PACS MARKET, BY END USER, 2024–2031 (USD MILLION)
TABLE 90 GERMANY: VENDOR NEUTRAL ARCHIVE (VNA) & PACS MARKET, BY PRODUCT TYPE, 2024–2031 (USD MILLION)
TABLE 91 GERMANY: VENDOR NEUTRAL ARCHIVE (VNA) MARKET, BY PRODUCT TYPE, 2024–2031 (USD MILLION)
TABLE 92 GERMANY: PACS MARKET, BY PRODUCT TYPE, 2024–2031 (USD MILLION)
TABLE 93 GERMANY: VENDOR NEUTRAL ARCHIVE (VNA) & PACS MARKET, BY MODALITY, 2024–2031 (USD MILLION)
TABLE 94 GERMANY: VENDOR NEUTRAL ARCHIVE (VNA) & PACS MARKET, BY DEPLOYMENT MODEL, 2024–2031 (USD MILLION)
TABLE 95 GERMANY: VENDOR NEUTRAL ARCHIVE (VNA) & PACS MARKET, BY VENDOR TYPE, 2024–2031 (USD MILLION)
TABLE 96 GERMANY: VENDOR NEUTRAL ARCHIVE (VNA) & PACS MARKET, BY APPLICATION, 2024–2031 (USD MILLION)
TABLE 97 GERMANY: VENDOR NEUTRAL ARCHIVE (VNA) & PACS MARKET, BY END USER, 2024–2031 (USD MILLION)
TABLE 98 UK: VENDOR NEUTRAL ARCHIVE (VNA) & PACS MARKET, BY PRODUCT TYPE, 2024–2031 (USD MILLION)
TABLE 99 UK: VENDOR NEUTRAL ARCHIVE (VNA) MARKET, BY PRODUCT TYPE, 2024–2031 (USD MILLION)
TABLE 100 UK: PACS MARKET, BY PRODUCT TYPE, 2024–2031 (USD MILLION)
TABLE 101 UK: VENDOR NEUTRAL ARCHIVE (VNA) & PACS MARKET, BY MODALITY, 2024–2031 (USD MILLION)
TABLE 102 UK: VENDOR NEUTRAL ARCHIVE (VNA) & PACS MARKET, BY DEPLOYMENT MODEL, 2024–2031 (USD MILLION)
TABLE 103 UK: VENDOR NEUTRAL ARCHIVE (VNA) & PACS MARKET, BY VENDOR TYPE, 2024–2031 (USD MILLION)
TABLE 104 UK: VENDOR NEUTRAL ARCHIVE (VNA) & PACS MARKET, BY APPLICATION, 2024–2031 (USD MILLION)
TABLE 105 UK: VENDOR NEUTRAL ARCHIVE (VNA) & PACS MARKET, BY END USER, 2024–2031 (USD MILLION)
TABLE 106 FRANCE: VENDOR NEUTRAL ARCHIVE (VNA) & PACS MARKET, BY PRODUCT TYPE, 2024–2031 (USD MILLION)
TABLE 107 FRANCE: VENDOR NEUTRAL ARCHIVE (VNA) MARKET, BY PRODUCT TYPE, 2024–2031 (USD MILLION)
TABLE 108 FRANCE: PACS MARKET, BY PRODUCT TYPE, 2024–2031 (USD MILLION)
TABLE 109 FRANCE: VENDOR NEUTRAL ARCHIVE (VNA) & PACS MARKET, BY MODALITY, 2024–2031 (USD MILLION)
TABLE 110 FRANCE: VENDOR NEUTRAL ARCHIVE (VNA) & PACS MARKET, BY DEPLOYMENT MODEL, 2024–2031 (USD MILLION)
TABLE 111 FRANCE: VENDOR NEUTRAL ARCHIVE (VNA) & PACS MARKET, BY VENDOR TYPE, 2024–2031 (USD MILLION)
TABLE 112 FRANCE: VENDOR NEUTRAL ARCHIVE (VNA) & PACS MARKET, BY APPLICATION, 2024–2031 (USD MILLION)
TABLE 113 FRANCE: VENDOR NEUTRAL ARCHIVE (VNA) & PACS MARKET, BY END USER, 2024–2031 (USD MILLION)
TABLE 114 ITALY: VENDOR NEUTRAL ARCHIVE (VNA) & PACS MARKET, BY PRODUCT TYPE, 2024–2031 (USD MILLION)
TABLE 115 ITALY: VENDOR NEUTRAL ARCHIVE (VNA) MARKET, BY PRODUCT TYPE, 2024–2031 (USD MILLION)
TABLE 116 ITALY: PACS MARKET, BY PRODUCT TYPE, 2024–2031 (USD MILLION)
TABLE 117 ITALY: VENDOR NEUTRAL ARCHIVE (VNA) & PACS MARKET, BY MODALITY, 2024–2031 (USD MILLION)
TABLE 118 ITALY: VENDOR NEUTRAL ARCHIVE (VNA) & PACS MARKET, BY DEPLOYMENT MODEL, 2024–2031 (USD MILLION)
TABLE 119 ITALY: VENDOR NEUTRAL ARCHIVE (VNA) & PACS MARKET, BY VENDOR TYPE, 2024–2031 (USD MILLION)
TABLE 120 ITALY: VENDOR NEUTRAL ARCHIVE (VNA) & PACS MARKET, BY APPLICATION, 2024–2031 (USD MILLION)
TABLE 121 ITALY: VENDOR NEUTRAL ARCHIVE (VNA) & PACS MARKET, BY END USER, 2024–2031 (USD MILLION)
TABLE 122 SPAIN: VENDOR NEUTRAL ARCHIVE (VNA) & PACS MARKET, BY PRODUCT TYPE, 2024–2031 (USD MILLION)
TABLE 123 SPAIN: VENDOR NEUTRAL ARCHIVE (VNA) MARKET, BY PRODUCT TYPE, 2024–2031 (USD MILLION)
TABLE 124 SPAIN: PACS MARKET, BY PRODUCT TYPE, 2024–2031 (USD MILLION)
TABLE 125 SPAIN: VENDOR NEUTRAL ARCHIVE (VNA) & PACS MARKET, BY MODALITY, 2024–2031 (USD MILLION)
TABLE 126 SPAIN: VENDOR NEUTRAL ARCHIVE (VNA) & PACS MARKET, BY DEPLOYMENT MODEL, 2024–2031 (USD MILLION)
TABLE 127 SPAIN: VENDOR NEUTRAL ARCHIVE (VNA) & PACS MARKET, BY VENDOR TYPE, 2024–2031 (USD MILLION)
TABLE 128 SPAIN: VENDOR NEUTRAL ARCHIVE (VNA) & PACS MARKET, BY APPLICATION, 2024–2031 (USD MILLION)
TABLE 129 SPAIN: VENDOR NEUTRAL ARCHIVE (VNA) & PACS MARKET, BY END USER, 2024–2031 (USD MILLION)
TABLE 130 REST OF EUROPE: VENDOR NEUTRAL ARCHIVE (VNA) & PACS MARKET, BY PRODUCT TYPE, 2024–2031 (USD MILLION)
TABLE 131 REST OF EUROPE: VENDOR NEUTRAL ARCHIVE (VNA) MARKET, BY PRODUCT TYPE, 2024–2031 (USD MILLION)
TABLE 132 REST OF EUROPE: PACS MARKET, BY PRODUCT TYPE, 2024–2031 (USD MILLION)
TABLE 133 REST OF EUROPE: VENDOR NEUTRAL ARCHIVE (VNA) & PACS MARKET, BY MODALITY, 2024–2031 (USD MILLION)
TABLE 134 REST OF EUROPE: VENDOR NEUTRAL ARCHIVE (VNA) & PACS MARKET, BY DEPLOYMENT MODEL, 2024–2031 (USD MILLION)
TABLE 135 REST OF EUROPE: VENDOR NEUTRAL ARCHIVE (VNA) & PACS MARKET, BY VENDOR TYPE, 2024–2031 (USD MILLION)
TABLE 136 REST OF EUROPE: VENDOR NEUTRAL ARCHIVE (VNA) & PACS MARKET, BY APPLICATION, 2024–2031 (USD MILLION)
TABLE 137 REST OF EUROPE: VENDOR NEUTRAL ARCHIVE (VNA) & PACS MARKET, BY END USER, 2024–2031 (USD MILLION)
TABLE 138 ASIA PACIFIC: VENDOR NEUTRAL ARCHIVE (VNA) & PACS MARKET, BY COUNTRY/REGION, 2024–2031 (USD MILLION)
TABLE 139 ASIA PACIFIC: VENDOR NEUTRAL ARCHIVE (VNA) & PACS MARKET, BY PRODUCT TYPE, 2024–2031 (USD MILLION)
TABLE 140 ASIA PACIFIC: VENDOR NEUTRAL ARCHIVE (VNA) MARKET, BY PRODUCT TYPE, 2024–2031 (USD MILLION)
TABLE 141 ASIA PACIFIC: PACS MARKET, BY PRODUCT TYPE, 2024–2031 (USD MILLION)
TABLE 142 ASIA PACIFIC: VENDOR NEUTRAL ARCHIVE (VNA) & PACS MARKET, BY MODALITY, 2024–2031 (USD MILLION)
TABLE 143 ASIA PACIFIC: VENDOR NEUTRAL ARCHIVE (VNA) & PACS MARKET, BY DEPLOYMENT MODEL, 2024–2031 (USD MILLION)
TABLE 144 ASIA PACIFIC: VENDOR NEUTRAL ARCHIVE (VNA) & PACS MARKET, BY VENDOR TYPE, 2024–2031 (USD MILLION)
TABLE 145 ASIA PACIFIC: VENDOR NEUTRAL ARCHIVE (VNA) & PACS MARKET, BY APPLICATION, 2024–2031 (USD MILLION)
TABLE 146 ASIA PACIFIC: VENDOR NEUTRAL ARCHIVE (VNA) & PACS MARKET, BY END USER, 2024–2031 (USD MILLION)
TABLE 147 JAPAN: VENDOR NEUTRAL ARCHIVE (VNA) & PACS MARKET, BY PRODUCT TYPE, 2024–2031 (USD MILLION)
TABLE 148 JAPAN: VENDOR NEUTRAL ARCHIVE (VNA) MARKET, BY PRODUCT TYPE, 2024–2031 (USD MILLION)
TABLE 149 JAPAN: PACS MARKET, BY PRODUCT TYPE, 2024–2031 (USD MILLION)
TABLE 150 JAPAN: VENDOR NEUTRAL ARCHIVE (VNA) & PACS MARKET, BY MODALITY, 2024–2031 (USD MILLION)
TABLE 151 JAPAN: VENDOR NEUTRAL ARCHIVE (VNA) & PACS MARKET, BY DEPLOYMENT MODEL, 2024–2031 (USD MILLION)
TABLE 152 JAPAN: VENDOR NEUTRAL ARCHIVE (VNA) & PACS MARKET, BY VENDOR TYPE, 2024–2031 (USD MILLION)
TABLE 153 JAPAN: VENDOR NEUTRAL ARCHIVE (VNA) & PACS MARKET, BY APPLICATION, 2024–2031 (USD MILLION)
TABLE 154 JAPAN: VENDOR NEUTRAL ARCHIVE (VNA) & PACS MARKET, BY END USER, 2024–2031 (USD MILLION)
TABLE 155 CHINA: VENDOR NEUTRAL ARCHIVE (VNA) & PACS MARKET, BY PRODUCT TYPE, 2024–2031 (USD MILLION)
TABLE 156 CHINA: VENDOR NEUTRAL ARCHIVE (VNA) MARKET, BY PRODUCT TYPE, 2024–2031 (USD MILLION)
TABLE 157 CHINA: PACS MARKET, BY PRODUCT TYPE, 2024–2031 (USD MILLION)
TABLE 158 CHINA: VENDOR NEUTRAL ARCHIVE (VNA) & PACS MARKET, BY MODALITY, 2024–2031 (USD MILLION)
TABLE 159 CHINA: VENDOR NEUTRAL ARCHIVE (VNA) & PACS MARKET, BY DEPLOYMENT MODEL, 2024–2031 (USD MILLION)
TABLE 160 CHINA: VENDOR NEUTRAL ARCHIVE (VNA) & PACS MARKET, BY VENDOR TYPE, 2024–2031 (USD MILLION)
TABLE 161 CHINA: VENDOR NEUTRAL ARCHIVE (VNA) & PACS MARKET, BY APPLICATION, 2024–2031 (USD MILLION)
TABLE 162 CHINA: VENDOR NEUTRAL ARCHIVE (VNA) & PACS MARKET, BY END USER, 2024–2031 (USD MILLION)
TABLE 163 INDIA: VENDOR NEUTRAL ARCHIVE (VNA) & PACS MARKET, BY PRODUCT TYPE, 2024–2031 (USD MILLION)
TABLE 164 INDIA: VENDOR NEUTRAL ARCHIVE (VNA) MARKET, BY PRODUCT TYPE, 2024–2031 (USD MILLION)
TABLE 165 INDIA: PACS MARKET, BY PRODUCT TYPE, 2024–2031 (USD MILLION)
TABLE 166 INDIA: VENDOR NEUTRAL ARCHIVE (VNA) & PACS MARKET, BY MODALITY, 2024–2031 (USD MILLION)
TABLE 167 INDIA: VENDOR NEUTRAL ARCHIVE (VNA) & PACS MARKET, BY DEPLOYMENT MODEL, 2024–2031 (USD MILLION)
TABLE 168 INDIA: VENDOR NEUTRAL ARCHIVE (VNA) & PACS MARKET, BY VENDOR TYPE, 2024–2031 (USD MILLION)
TABLE 169 INDIA: VENDOR NEUTRAL ARCHIVE (VNA) & PACS MARKET, BY APPLICATION, 2024–2031 (USD MILLION)
TABLE 170 INDIA: VENDOR NEUTRAL ARCHIVE (VNA) & PACS MARKET, BY END USER, 2024–2031 (USD MILLION)
TABLE 171 REST OF ASIA PACIFIC: VENDOR NEUTRAL ARCHIVE (VNA) & PACS MARKET, BY PRODUCT TYPE, 2024–2031 (USD MILLION)
TABLE 172 REST OF ASIA PACIFIC: VENDOR NEUTRAL ARCHIVE (VNA) MARKET, BY PRODUCT TYPE, 2024–2031 (USD MILLION)
TABLE 173 REST OF ASIA PACIFIC: PACS MARKET, BY PRODUCT TYPE, 2024–2031 (USD MILLION)
TABLE 174 REST OF ASIA PACIFIC: VENDOR NEUTRAL ARCHIVE (VNA) & PACS MARKET, BY MODALITY, 2024–2031 (USD MILLION)
TABLE 175 REST OF ASIA PACIFIC: VENDOR NEUTRAL ARCHIVE (VNA) & PACS MARKET, BY DEPLOYMENT MODEL, 2024–2031 (USD MILLION)
TABLE 176 REST OF ASIA PACIFIC: VENDOR NEUTRAL ARCHIVE (VNA) & PACS MARKET, BY VENDOR TYPE, 2024–2031 (USD MILLION)
TABLE 177 REST OF ASIA PACIFIC: VENDOR NEUTRAL ARCHIVE (VNA) & PACS MARKET, BY APPLICATION, 2024–2031 (USD MILLION)
TABLE 178 REST OF ASIA PACIFIC: VENDOR NEUTRAL ARCHIVE (VNA) & PACS MARKET, BY END USER, 2024–2031 (USD MILLION)
TABLE 179 LATIN AMERICA: VENDOR NEUTRAL ARCHIVE (VNA) & PACS MARKET, BY COUNTRY/REGION, 2024–2031 (USD MILLION)
TABLE 180 LATIN AMERICA: VENDOR NEUTRAL ARCHIVE (VNA) & PACS MARKET, BY PRODUCT TYPE, 2024–2031 (USD MILLION)
TABLE 181 LATIN AMERICA: VENDOR NEUTRAL ARCHIVE (VNA) MARKET, BY PRODUCT TYPE, 2024–2031 (USD MILLION)
TABLE 182 LATIN AMERICA: PACS MARKET, BY PRODUCT TYPE, 2024–2031 (USD MILLION)
TABLE 183 LATIN AMERICA: VENDOR NEUTRAL ARCHIVE (VNA) & PACS MARKET, BY MODALITY, 2024–2031 (USD MILLION)
TABLE 184 LATIN AMERICA: VENDOR NEUTRAL ARCHIVE (VNA) & PACS MARKET, BY DEPLOYMENT MODEL, 2024–2031 (USD MILLION)
TABLE 185 LATIN AMERICA: VENDOR NEUTRAL ARCHIVE (VNA) & PACS MARKET, BY VENDOR TYPE, 2024–2031 (USD MILLION)
TABLE 186 LATIN AMERICA: VENDOR NEUTRAL ARCHIVE (VNA) & PACS MARKET, BY APPLICATION, 2024–2031 (USD MILLION)
TABLE 187 LATIN AMERICA: VENDOR NEUTRAL ARCHIVE (VNA) & PACS MARKET, BY END USER, 2024–2031 (USD MILLION)
TABLE 188 BRAZIL: VENDOR NEUTRAL ARCHIVE (VNA) & PACS MARKET, BY PRODUCT TYPE, 2024–2031 (USD MILLION)
TABLE 189 BRAZIL: VENDOR NEUTRAL ARCHIVE (VNA) MARKET, BY PRODUCT TYPE, 2024–2031 (USD MILLION)
TABLE 190 BRAZIL: PACS MARKET, BY PRODUCT TYPE, 2024–2031 (USD MILLION)
TABLE 191 BRAZIL: VENDOR NEUTRAL ARCHIVE (VNA) & PACS MARKET, BY MODALITY, 2024–2031 (USD MILLION)
TABLE 192 BRAZIL: VENDOR NEUTRAL ARCHIVE (VNA) & PACS MARKET, BY DEPLOYMENT MODEL, 2024–2031 (USD MILLION)
TABLE 193 BRAZIL: VENDOR NEUTRAL ARCHIVE (VNA) & PACS MARKET, BY VENDOR TYPE, 2024–2031 (USD MILLION)
TABLE 194 BRAZIL: VENDOR NEUTRAL ARCHIVE (VNA) & PACS MARKET, BY APPLICATION, 2024–2031 (USD MILLION)
TABLE 195 BRAZIL: VENDOR NEUTRAL ARCHIVE (VNA) & PACS MARKET, BY END USER, 2024–2031 (USD MILLION)
TABLE 196 MEXICO: VENDOR NEUTRAL ARCHIVE (VNA) & PACS MARKET, BY PRODUCT TYPE, 2024–2031 (USD MILLION)
TABLE 197 MEXICO: VENDOR NEUTRAL ARCHIVE (VNA) MARKET, BY PRODUCT TYPE, 2024–2031 (USD MILLION)
TABLE 198 MEXICO: PACS MARKET, BY PRODUCT TYPE, 2024–2031 (USD MILLION)
TABLE 199 MEXICO: VENDOR NEUTRAL ARCHIVE (VNA) & PACS MARKET, BY MODALITY, 2024–2031 (USD MILLION)
TABLE 200 MEXICO: VENDOR NEUTRAL ARCHIVE (VNA) & PACS MARKET, BY DEPLOYMENT MODEL, 2024–2031 (USD MILLION)
TABLE 201 MEXICO: VENDOR NEUTRAL ARCHIVE (VNA) & PACS MARKET, BY VENDOR TYPE, 2024–2031 (USD MILLION)
TABLE 202 MEXICO: VENDOR NEUTRAL ARCHIVE (VNA) & PACS MARKET, BY APPLICATION, 2024–2031 (USD MILLION)
TABLE 203 MEXICO: VENDOR NEUTRAL ARCHIVE (VNA) & PACS MARKET, BY END USER, 2024–2031 (USD MILLION)
TABLE 204 REST OF LATIN AMERICA: VENDOR NEUTRAL ARCHIVE (VNA) & PACS MARKET, BY PRODUCT TYPE, 2024–2031 (USD MILLION)
TABLE 205 REST OF LATIN AMERICA: VENDOR NEUTRAL ARCHIVE (VNA) MARKET, BY PRODUCT TYPE, 2024–2031 (USD MILLION)
TABLE 206 REST OF LATIN AMERICA: PACS MARKET, BY PRODUCT TYPE, 2024–2031 (USD MILLION)
TABLE 207 REST OF LATIN AMERICA: VENDOR NEUTRAL ARCHIVE (VNA) & PACS MARKET, BY MODALITY, 2024–2031 (USD MILLION)
TABLE 208 REST OF LATIN AMERICA: VENDOR NEUTRAL ARCHIVE (VNA) & PACS MARKET, BY DEPLOYMENT MODEL, 2024–2031 (USD MILLION)
TABLE 209 REST OF LATIN AMERICA: VENDOR NEUTRAL ARCHIVE (VNA) & PACS MARKET, BY VENDOR TYPE, 2024–2031 (USD MILLION)
TABLE 210 REST OF LATIN AMERICA: VENDOR NEUTRAL ARCHIVE (VNA) & PACS MARKET, BY APPLICATION, 2024–2031 (USD MILLION)
TABLE 211 REST OF LATIN AMERICA: VENDOR NEUTRAL ARCHIVE (VNA) & PACS MARKET, BY END USER, 2024–2031 (USD MILLION)
TABLE 212 MIDDLE EAST & AFRICA: VENDOR NEUTRAL ARCHIVE (VNA) & PACS MARKET, BY COUNTRY/REGION, 2024–2031 (USD MILLION)
TABLE 213 MIDDLE EAST & AFRICA: VENDOR NEUTRAL ARCHIVE (VNA) & PACS MARKET, BY PRODUCT TYPE, 2024–2031 (USD MILLION)
TABLE 214 MIDDLE EAST & AFRICA: VENDOR NEUTRAL ARCHIVE (VNA) MARKET, BY PRODUCT TYPE, 2024–2031 (USD MILLION)
TABLE 215 MIDDLE EAST & AFRICA: PACS MARKET, BY PRODUCT TYPE, 2024–2031 (USD MILLION)
TABLE 216 MIDDLE EAST & AFRICA: VENDOR NEUTRAL ARCHIVE (VNA) & PACS MARKET, BY MODALITY, 2024–2031 (USD MILLION)
TABLE 217 MIDDLE EAST & AFRICA: VENDOR NEUTRAL ARCHIVE (VNA) & PACS MARKET, BY DEPLOYMENT MODEL, 2024–2031 (USD MILLION)
TABLE 218 MIDDLE EAST & AFRICA: VENDOR NEUTRAL ARCHIVE (VNA) & PACS MARKET, BY VENDOR TYPE, 2024–2031 (USD MILLION)
TABLE 219 MIDDLE EAST & AFRICA: VENDOR NEUTRAL ARCHIVE (VNA) & PACS MARKET, BY APPLICATION, 2024–2031 (USD MILLION)
TABLE 220 MIDDLE EAST & AFRICA: VENDOR NEUTRAL ARCHIVE (VNA) & PACS MARKET, BY END USER, 2024–2031 (USD MILLION)
TABLE 221 GCC COUNTRIES: VENDOR NEUTRAL ARCHIVE (VNA) & PACS MARKET, BY PRODUCT TYPE, 2024–2031 (USD MILLION)
TABLE 222 GCC COUNTRIES: VENDOR NEUTRAL ARCHIVE (VNA) MARKET, BY PRODUCT TYPE, 2024–2031 (USD MILLION)
TABLE 223 GCC COUNTRIES: PACS MARKET, BY PRODUCT TYPE, 2024–2031 (USD MILLION)
TABLE 224 GCC COUNTRIES: VENDOR NEUTRAL ARCHIVE (VNA) & PACS MARKET, BY MODALITY, 2024–2031 (USD MILLION)
TABLE 225 GCC COUNTRIES: VENDOR NEUTRAL ARCHIVE (VNA) & PACS MARKET, BY DEPLOYMENT MODEL, 2024–2031 (USD MILLION)
TABLE 226 GCC COUNTRIES: VENDOR NEUTRAL ARCHIVE (VNA) & PACS MARKET, BY VENDOR TYPE, 2024–2031 (USD MILLION)
TABLE 227 GCC COUNTRIES: VENDOR NEUTRAL ARCHIVE (VNA) & PACS MARKET, BY APPLICATION, 2024–2031 (USD MILLION)
TABLE 228 GCC COUNTRIES: VENDOR NEUTRAL ARCHIVE (VNA) & PACS MARKET, BY END USER, 2024–2031 (USD MILLION)
TABLE 229 REST OF MIDDLE EAST AND AFRICA: VENDOR NEUTRAL ARCHIVE (VNA) & PACS MARKET, BY PRODUCT TYPE, 2024–2031 (USD MILLION)
TABLE 230 REST OF MIDDLE EAST AND AFRICA: VENDOR NEUTRAL ARCHIVE (VNA) MARKET, BY PRODUCT TYPE, 2024–2031 (USD MILLION)
TABLE 231 REST OF MIDDLE EAST AND AFRICA: PACS MARKET, BY PRODUCT TYPE, 2024–2031 (USD MILLION)
TABLE 232 REST OF MIDDLE EAST AND AFRICA: VENDOR NEUTRAL ARCHIVE (VNA) & PACS MARKET, BY MODALITY, 2024–2031 (USD MILLION)
TABLE 233 REST OF MIDDLE EAST AND AFRICA: VENDOR NEUTRAL ARCHIVE (VNA) & PACS MARKET, BY DEPLOYMENT MODEL, 2024–2031 (USD MILLION)
TABLE 234 REST OF MIDDLE EAST AND AFRICA: VENDOR NEUTRAL ARCHIVE (VNA) & PACS MARKET, BY VENDOR TYPE, 2024–2031 (USD MILLION)
TABLE 235 REST OF MIDDLE EAST AND AFRICA: VENDOR NEUTRAL ARCHIVE (VNA) & PACS MARKET, BY APPLICATION, 2024–2031 (USD MILLION)
TABLE 236 REST OF MIDDLE EAST AND AFRICA: VENDOR NEUTRAL ARCHIVE (VNA) & PACS MARKET, BY END USER, 2024–2031 (USD MILLION)
TABLE 237 OVERVIEW OF STRATEGIES ADOPTED BY KEY PLAYERS IN VENDOR NEUTRAL ARCHIVE (VNA) & PACS MARKET, JANUARY 2023–APRIL 2026
TABLE 238 VENDOR NEUTRAL ARCHIVE (VNA) & PACS MARKET: DEGREE OF COMPETITION
TABLE 239 VENDOR NEUTRAL ARCHIVE (VNA) & PACS MARKET: PRODUCT FOOTPRINT, 2025
TABLE 240 VENDOR NEUTRAL ARCHIVE (VNA) & PACS MARKET: DEPLOYMENT FOOTPRINT, 2025
TABLE 241 VENDOR NEUTRAL ARCHIVE (VNA) & PACS MARKET: END USER FOOTPRINT, 2025
TABLE 242 VENDOR NEUTRAL ARCHIVE (VNA) & PACS MARKET: REGIONAL FOOTPRINT, 2025
TABLE 243 VENDOR NEUTRAL ARCHIVE (VNA) & PACS MARKET: DETAILED LIST OF KEY STARTUPS/SMES, 2025
TABLE 244 VENDOR NEUTRAL ARCHIVE (VNA) & PACS MARKET: COMPETITIVE BENCHMARKING OF STARTUPS/SMES, 2025
TABLE 245 VENDOR NEUTRAL ARCHIVE (VNA) & PACS MARKET: PRODUCT LAUNCHES & UPGRADES, JANUARY 2023–APRIL 2026
TABLE 246 VENDOR NEUTRAL ARCHIVE (VNA) & PACS MARKET: DEALS, JANUARY 2023–APRIL 2026
TABLE 247 VENDOR NEUTRAL ARCHIVE (VNA) & PACS MARKET: OTHER DEVELOPMENTS, JANUARY 2023–APRIL 2026
TABLE 248 AGFA-GEVAERT GROUP: BUSINESS OVERVIEW
TABLE 249 AGFA-GEVAERT GROUP: SOLUTIONS OFFERED
TABLE 250 AGFA-GEVAERT GROUP: DEALS
TABLE 251 FUJIFILM HOLDINGS CORPORATION: COMPANY OVERVIEW
TABLE 252 FUJIFILM HOLDINGS CORPORATION: SOLUTIONS OFFERED
TABLE 253 FUJIFILM HOLDINGS CORPORATION: DEALS
TABLE 254 FUJIFILM HOLDINGS CORPORATION: OTHER DEVELOPMENTS
TABLE 255 SECTRA AB: BUSINESS OVERVIEW
TABLE 256 SECTRA AB: SOLUTIONS OFFERED
TABLE 257 GE HEALTHCARE: BUSINESS OVERVIEW
TABLE 258 GE HEALTHCARE: SOLUTIONS OFFERED
TABLE 259 GE HEALTHCARE: PRODUCTS LAUNCHES
TABLE 260 GE HEALTHCARE: DEALS
TABLE 261 MERATIVE: BUSINESS OVERVIEW
TABLE 262 MERATIVE: SOLUTIONS OFFERED
TABLE 263 MERATIVE: DEALS
TABLE 264 KONINKLIJKE PHILIPS N.V.: BUSINESS OVERVIEW
TABLE 265 KONINKLIJKE PHILIPS N.V.: SOLUTIONS OFFERED
TABLE 266 KONINKLIJKE PHILIPS N.V.: PRODUCT LAUNCHES
TABLE 267 KONINKLIJKE PHILIPS N.V.: DEALS
TABLE 268 CANON MEDICAL SYSTEMS CORPORATION: COMPANY OVERVIEW
TABLE 269 CANON MEDICAL SYSTEMS CORPORATION: SOLUTIONS OFFERED
TABLE 270 CANON MEDICAL SYSTEMS CORPORATION: DEALS
TABLE 271 PAXERAHEALTH: BUSINESS OVERVIEW
TABLE 272 PAXERAHEALTH: SOLUTIONS OFFERED
TABLE 273 NOVARAD CORPORATION: BUSINESS OVERVIEW
TABLE 274 NOVARAD CORPORATION: SOLUTIONS OFFERED
TABLE 275 HYLAND SOFTWARE, INC.: BUSINESS OVERVIEW
TABLE 276 HYLAND SOFTWARE, INC.: SOLUTIONS OFFERED
TABLE 277 HYLAND SOFTWARE, INC.: DEALS
TABLE 278 SIEMENS HEALTHCARE LIMITED: BUSINESS OVERVIEW
TABLE 279 SIEMENS HEALTHCARE LIMITED: SOLUTIONS OFFERED
TABLE 280 SIEMENS HEALTHCARE LIMITED: DEALS
TABLE 281 BRIDGEHEAD SOFTWARE LTD.: BUSINESS OVERVIEW
TABLE 282 BRIDGEHEAD SOFTWARE LTD.: SOLUTIONS OFFERED
TABLE 283 CANOPY PARTNERS: BUSINESS OVERVIEW
TABLE 284 CANOPY PARTNERS: SOLUTIONS OFFERED
TABLE 285 CRELIOHEALTH INC.: BUSINESS OVERVIEW
TABLE 286 CRELIOHEALTH INC.: SOLUTIONS OFFERED
TABLE 287 ASPYRA, LLC: BUSINESS OVERVIEW
TABLE 288 ASPYRA, LLC: SOLUTIONS OFFERED
TABLE 289 POSTDICOM: BUSINESS OVERVIEW
TABLE 290 POSTDICOM: SOLUTIONS OFFERED
TABLE 291 MEDICASOFT: BUSINESS OVERVIEW
TABLE 292 MEDICASOFT: SOLUTIONS OFFERED
TABLE 293 ESAOTE SPA.: BUSINESS OVERVIEW
TABLE 294 ESAOTE SPA: SOLUTIONS OFFERED
TABLE 295 ESAOTE SPA: PRODUCT LAUNCHES
TABLE 296 VISUS HEALTH IT GMBH: BUSINESS OVERVIEW
TABLE 297 VISUS HEALTH IT GMBH: SOLUTIONS OFFERED
TABLE 1 EXCHANGE RATES UTILIZED FOR CONVERSION TO USD
TABLE 2 IMPACT OF PORTER’S FIVE FORCES ON VENDOR NEUTRAL ARCHIVE (VNA) & PACS MARKET
TABLE 3 VENDOR NEUTRAL ARCHIVE (VNA) & PACS MARKET: ROLE IN ECOSYSTEM
TABLE 4 AVERAGE SELLING PRICE OF PACS SOLUTIONS, BY PRODUCT TYPE (USD)
TABLE 5 AVERAGE SELLING PRICE OF VNA SOLUTIONS, BY PRODUCT TYPE (USD)
TABLE 6 KEY CONFERENCES AND EVENTS, 2026–2027
TABLE 7 JURISDICTION ANALYSIS OF TOP APPLICANT COUNTRIES FOR AI IN TELEHEALTH & TELEMEDICINE
TABLE 8 LIST OF PATENTS/PATENT APPLICATIONS, 2015–2025
TABLE 9 NORTH AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
TABLE 10 EUROPE: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
TABLE 11 ASIA PACIFIC: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
TABLE 12 ROW: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
TABLE 13 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS OF FOUR END USERS
TABLE 14 KEY BUYING CRITERIA FOR FOUR END USERS
TABLE 15 UNMET NEEDS IN VENDOR NEUTRAL ARCHIVE (VNA) & PACS MARKET
TABLE 16 END-USER EXPECTATIONS IN VENDOR NEUTRAL ARCHIVE (VNA) & PACS MARKET
TABLE 17 VENDOR NEUTRAL ARCHIVE (VNA) & PACS MARKET, BY PRODUCT TYPE, 2024–2031 (USD MILLION)
TABLE 18 VENDOR NEUTRAL ARCHIVE (VNA) MARKET, BY PRODUCT TYPE, 2024–2031 (USD MILLION)
TABLE 19 VENDOR NEUTRAL ARCHIVE (VNA) MARKET, BY COUNTRY/REGION, 2024–2031 (USD MILLION)
TABLE 20 DEPARTMENT VENDOR NEUTRAL ARCHIVE (VNA) MARKET, BY COUNTRY/REGION, 2024–2031 (USD MILLION)
TABLE 21 MULTI-DEPARTMENT VENDOR NEUTRAL ARCHIVE (VNA) MARKET, BY COUNTRY/REGION, 2024–2031 (USD MILLION)
TABLE 22 MULTI-SITE VENDOR NEUTRAL ARCHIVE (VNA) MARKET, BY COUNTRY/REGION, 2024–2031 (USD MILLION)
TABLE 23 PACS MARKET, BY PRODUCT TYPE, 2024–2031 (USD MILLION)
TABLE 24 PACS MARKET, BY COUNTRY/REGION, 2024–2031 (USD MILLION)
TABLE 25 DEPARTMENT PACS MARKET, BY COUNTRY/REGION, 2024–2031 (USD MILLION)
TABLE 26 MULTI-DEPARTMENT PACS MARKET, BY COUNTRY/REGION, 2024–2031 (USD MILLION)
TABLE 27 MULTI-SITE PACS MARKET, BY COUNTRY/REGION, 2024–2031 (USD MILLION)
TABLE 28 VENDOR NEUTRAL ARCHIVE (VNA) & PACS MARKET, BY MODALITY, 2024–2031 (USD MILLION)
TABLE 29 VENDOR NEUTRAL ARCHIVE (VNA) & PACS MARKET FOR CT, BY COUNTRY/REGION, 2024–2031 (USD MILLION)
TABLE 30 VENDOR NEUTRAL ARCHIVE (VNA) & PACS MARKET FOR MAMMOGRAPHY, BY COUNTRY/REGION, 2024–2031 (USD MILLION)
TABLE 31 VENDOR NEUTRAL ARCHIVE (VNA) & PACS MARKET FOR ULTRASOUND, BY COUNTRY/REGION, 2024–2031 (USD MILLION)
TABLE 32 VENDOR NEUTRAL ARCHIVE (VNA) & PACS MARKET FOR MAGNETIC RESONANCE IMAGING (MRI), BY COUNTRY/REGION, 2024–2031 (USD MILLION)
TABLE 33 VENDOR NEUTRAL ARCHIVE (VNA) & PACS MARKET FOR X-RAY, BY COUNTRY/REGION, 2024–2031 (USD MILLION)
TABLE 34 VENDOR NEUTRAL ARCHIVE (VNA) & PACS MARKET FOR PET, BY COUNTRY/REGION, 2024–2031 (USD MILLION)
TABLE 35 VENDOR NEUTRAL ARCHIVE (VNA) & PACS MARKET, BY DEPLOYMENT MODEL, 2024–2031 (USD MILLION)
TABLE 36 ON-PREMISE VENDOR NEUTRAL ARCHIVE (VNA) & PACS MARKET, BY COUNTRY/REGION, 2024–2031 (USD MILLION)
TABLE 37 CLOUD-BASED VENDOR NEUTRAL ARCHIVE (VNA) & PACS MARKET, BY COUNTRY/REGION, 2024–2031 (USD MILLION)
TABLE 38 HYBRID VENDOR NEUTRAL ARCHIVE (VNA) & PACS MARKET, BY COUNTRY/REGION, 2024–2031 (USD MILLION)
TABLE 39 VENDOR NEUTRAL ARCHIVE (VNA) & PACS MARKET, BY VENDOR TYPE, 2024–2031 (USD MILLION)
TABLE 40 INDEPENDENT VENDOR NEUTRAL ARCHIVE (VNA) & PACS MARKET, BY COUNTRY/REGION, 2024–2031 (USD MILLION)
TABLE 41 THIRD-PARTY VENDOR NEUTRAL ARCHIVE (VNA) & PACS MARKET, BY COUNTRY/REGION, 2024–2031 (USD MILLION)
TABLE 42 VENDOR NEUTRAL ARCHIVE (VNA) & PACS MARKET, BY APPLICATION, 2024–2031 (USD MILLION)
TABLE 43 VENDOR NEUTRAL ARCHIVE (VNA) & PACS MARKET FOR CARDIOLOGY APPLICATIONS, BY COUNTRY/REGION, 2024–2031 (USD MILLION)
TABLE 44 VENDOR NEUTRAL ARCHIVE (VNA) & PACS MARKET FOR ORTHOPEDIC APPLICATIONS, BY COUNTRY/REGION, 2024–2031 (USD MILLION)
TABLE 45 VENDOR NEUTRAL ARCHIVE (VNA) & PACS MARKET FOR ONCOLOGY APPLICATIONS, BY COUNTRY/REGION, 2024–2031 (USD MILLION)
TABLE 46 VENDOR NEUTRAL ARCHIVE (VNA) & PACS MARKET FOR NEUROLOGY APPLICATIONS, BY COUNTRY/REGION, 2024–2031 (USD MILLION)
TABLE 47 VENDOR NEUTRAL ARCHIVE (VNA) & PACS MARKET FOR OBSTETRICS AND GYNECOLOGY APPLICATIONS, BY COUNTRY/REGION, 2024–2031 (USD MILLION)
TABLE 48 VENDOR NEUTRAL ARCHIVE (VNA) & PACS MARKET FOR OTHER APPLICATIONS, BY COUNTRY/REGION, 2024–2031 (USD MILLION)
TABLE 49 VENDOR NEUTRAL ARCHIVE (VNA) & PACS MARKET, BY END USER, 2024–2031 (USD MILLION)
TABLE 50 VENDOR NEUTRAL ARCHIVE (VNA) & PACS MARKET FOR HOSPITALS & CLINICS, BY COUNTRY/REGION, 2024–2031 (USD MILLION)
TABLE 51 VENDOR NEUTRAL ARCHIVE (VNA) & PACS MARKET FOR DIAGNOSTIC CENTERS, BY COUNTRY/REGION, 2024–2031 (USD MILLION)
TABLE 52 VENDOR NEUTRAL ARCHIVE (VNA) & PACS MARKET FOR AMBULATORY SURGICAL CENTERS, BY COUNTRY/REGION, 2024–2031 (USD MILLION)
TABLE 53 VENDOR NEUTRAL ARCHIVE (VNA) & PACS MARKET FOR OTHER END USERS, BY COUNTRY/REGION, 2024–2031 (USD MILLION)
TABLE 54 VENDOR NEUTRAL ARCHIVE (VNA) & PACS MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 55 NORTH AMERICA: VENDOR NEUTRAL ARCHIVE (VNA) & PACS MARKET, BY COUNTRY/REGION, 2024–2031 (USD MILLION)
TABLE 56 NORTH AMERICA: VENDOR NEUTRAL ARCHIVE (VNA) & PACS MARKET, BY PRODUCT TYPE, 2024–2031 (USD MILLION)
TABLE 57 NORTH AMERICA: VENDOR NEUTRAL ARCHIVE (VNA) MARKET, BY PRODUCT TYPE, 2024–2031 (USD MILLION)
TABLE 58 NORTH AMERICA: PACS MARKET, BY PRODUCT TYPE, 2024–2031 (USD MILLION)
TABLE 59 NORTH AMERICA: VENDOR NEUTRAL ARCHIVE (VNA) & PACS MARKET, BY MODALITY, 2024–2031 (USD MILLION)
TABLE 60 NORTH AMERICA: VENDOR NEUTRAL ARCHIVE (VNA) & PACS MARKET, BY DEPLOYMENT MODEL, 2024–2031 (USD MILLION)
TABLE 61 NORTH AMERICA: VENDOR NEUTRAL ARCHIVE (VNA) & PACS MARKET, BY VENDOR TYPE, 2024–2031 (USD MILLION)
TABLE 62 NORTH AMERICA: VENDOR NEUTRAL ARCHIVE (VNA) & PACS MARKET, BY APPLICATION, 2024–2031 (USD MILLION)
TABLE 63 NORTH AMERICA: VENDOR NEUTRAL ARCHIVE (VNA) & PACS MARKET, BY END USER, 2024–2031 (USD MILLION)
TABLE 64 US: KEY MACRO INDICATORS
TABLE 65 US: VENDOR NEUTRAL ARCHIVE (VNA) & PACS MARKET, BY PRODUCT TYPE, 2024–2031 (USD MILLION)
TABLE 66 US: VENDOR NEUTRAL ARCHIVE (VNA) MARKET, BY PRODUCT TYPE, 2024–2031 (USD MILLION)
TABLE 67 US: PACS MARKET, BY PRODUCT TYPE, 2024–2031 (USD MILLION)
TABLE 68 US: VENDOR NEUTRAL ARCHIVE (VNA) & PACS MARKET, BY MODALITY, 2024–2031 (USD MILLION)
TABLE 69 US: VENDOR NEUTRAL ARCHIVE (VNA) & PACS MARKET, BY DEPLOYMENT MODEL, 2024–2031 (USD MILLION)
TABLE 70 US: VENDOR NEUTRAL ARCHIVE (VNA) & PACS MARKET, BY VENDOR TYPE, 2024–2031 (USD MILLION)
TABLE 71 US: VENDOR NEUTRAL ARCHIVE (VNA) & PACS MARKET, BY APPLICATION, 2024–2031 (USD MILLION)
TABLE 72 US: VENDOR NEUTRAL ARCHIVE (VNA) & PACS MARKET, BY END USER, 2024–2031 (USD MILLION)
TABLE 73 CANADA: VENDOR NEUTRAL ARCHIVE (VNA) & PACS MARKET, BY PRODUCT TYPE, 2024–2031 (USD MILLION)
TABLE 74 CANADA: VENDOR NEUTRAL ARCHIVE (VNA) MARKET, BY PRODUCT TYPE, 2024–2031 (USD MILLION)
TABLE 75 CANADA: PACS MARKET, BY PRODUCT TYPE, 2024–2031 (USD MILLION)
TABLE 76 CANADA: VENDOR NEUTRAL ARCHIVE (VNA) & PACS MARKET, BY MODALITY, 2024–2031 (USD MILLION)
TABLE 77 CANADA: VENDOR NEUTRAL ARCHIVE (VNA) & PACS MARKET, BY DEPLOYMENT MODEL, 2024–2031 (USD MILLION)
TABLE 78 CANADA: VENDOR NEUTRAL ARCHIVE (VNA) & PACS MARKET, BY VENDOR TYPE, 2024–2031 (USD MILLION)
TABLE 79 CANADA: VENDOR NEUTRAL ARCHIVE (VNA) & PACS MARKET, BY APPLICATION, 2024–2031 (USD MILLION)
TABLE 80 CANADA: VENDOR NEUTRAL ARCHIVE (VNA) & PACS MARKET, BY END USER, 2024–2031 (USD MILLION)
TABLE 81 EUROPE: VENDOR NEUTRAL ARCHIVE (VNA) & PACS MARKET, BY COUNTRY/REGION, 2024–2031 (USD MILLION)
TABLE 82 EUROPE: VENDOR NEUTRAL ARCHIVE (VNA) & PACS MARKET, BY PRODUCT TYPE, 2024–2031 (USD MILLION)
TABLE 83 EUROPE: VENDOR NEUTRAL ARCHIVE (VNA) MARKET, BY PRODUCT TYPE, 2024–2031 (USD MILLION)
TABLE 84 EUROPE: PACS MARKET, BY PRODUCT TYPE, 2024–2031 (USD MILLION)
TABLE 85 EUROPE: VENDOR NEUTRAL ARCHIVE (VNA) & PACS MARKET, BY MODALITY, 2024–2031 (USD MILLION)
TABLE 86 EUROPE: VENDOR NEUTRAL ARCHIVE (VNA) & PACS MARKET, BY DEPLOYMENT MODEL, 2024–2031 (USD MILLION)
TABLE 87 EUROPE: VENDOR NEUTRAL ARCHIVE (VNA) & PACS MARKET, BY VENDOR TYPE, 2024–2031 (USD MILLION)
TABLE 88 EUROPE: VENDOR NEUTRAL ARCHIVE (VNA) & PACS MARKET, BY APPLICATION, 2024–2031 (USD MILLION)
TABLE 89 EUROPE: VENDOR NEUTRAL ARCHIVE (VNA) & PACS MARKET, BY END USER, 2024–2031 (USD MILLION)
TABLE 90 GERMANY: VENDOR NEUTRAL ARCHIVE (VNA) & PACS MARKET, BY PRODUCT TYPE, 2024–2031 (USD MILLION)
TABLE 91 GERMANY: VENDOR NEUTRAL ARCHIVE (VNA) MARKET, BY PRODUCT TYPE, 2024–2031 (USD MILLION)
TABLE 92 GERMANY: PACS MARKET, BY PRODUCT TYPE, 2024–2031 (USD MILLION)
TABLE 93 GERMANY: VENDOR NEUTRAL ARCHIVE (VNA) & PACS MARKET, BY MODALITY, 2024–2031 (USD MILLION)
TABLE 94 GERMANY: VENDOR NEUTRAL ARCHIVE (VNA) & PACS MARKET, BY DEPLOYMENT MODEL, 2024–2031 (USD MILLION)
TABLE 95 GERMANY: VENDOR NEUTRAL ARCHIVE (VNA) & PACS MARKET, BY VENDOR TYPE, 2024–2031 (USD MILLION)
TABLE 96 GERMANY: VENDOR NEUTRAL ARCHIVE (VNA) & PACS MARKET, BY APPLICATION, 2024–2031 (USD MILLION)
TABLE 97 GERMANY: VENDOR NEUTRAL ARCHIVE (VNA) & PACS MARKET, BY END USER, 2024–2031 (USD MILLION)
TABLE 98 UK: VENDOR NEUTRAL ARCHIVE (VNA) & PACS MARKET, BY PRODUCT TYPE, 2024–2031 (USD MILLION)
TABLE 99 UK: VENDOR NEUTRAL ARCHIVE (VNA) MARKET, BY PRODUCT TYPE, 2024–2031 (USD MILLION)
TABLE 100 UK: PACS MARKET, BY PRODUCT TYPE, 2024–2031 (USD MILLION)
TABLE 101 UK: VENDOR NEUTRAL ARCHIVE (VNA) & PACS MARKET, BY MODALITY, 2024–2031 (USD MILLION)
TABLE 102 UK: VENDOR NEUTRAL ARCHIVE (VNA) & PACS MARKET, BY DEPLOYMENT MODEL, 2024–2031 (USD MILLION)
TABLE 103 UK: VENDOR NEUTRAL ARCHIVE (VNA) & PACS MARKET, BY VENDOR TYPE, 2024–2031 (USD MILLION)
TABLE 104 UK: VENDOR NEUTRAL ARCHIVE (VNA) & PACS MARKET, BY APPLICATION, 2024–2031 (USD MILLION)
TABLE 105 UK: VENDOR NEUTRAL ARCHIVE (VNA) & PACS MARKET, BY END USER, 2024–2031 (USD MILLION)
TABLE 106 FRANCE: VENDOR NEUTRAL ARCHIVE (VNA) & PACS MARKET, BY PRODUCT TYPE, 2024–2031 (USD MILLION)
TABLE 107 FRANCE: VENDOR NEUTRAL ARCHIVE (VNA) MARKET, BY PRODUCT TYPE, 2024–2031 (USD MILLION)
TABLE 108 FRANCE: PACS MARKET, BY PRODUCT TYPE, 2024–2031 (USD MILLION)
TABLE 109 FRANCE: VENDOR NEUTRAL ARCHIVE (VNA) & PACS MARKET, BY MODALITY, 2024–2031 (USD MILLION)
TABLE 110 FRANCE: VENDOR NEUTRAL ARCHIVE (VNA) & PACS MARKET, BY DEPLOYMENT MODEL, 2024–2031 (USD MILLION)
TABLE 111 FRANCE: VENDOR NEUTRAL ARCHIVE (VNA) & PACS MARKET, BY VENDOR TYPE, 2024–2031 (USD MILLION)
TABLE 112 FRANCE: VENDOR NEUTRAL ARCHIVE (VNA) & PACS MARKET, BY APPLICATION, 2024–2031 (USD MILLION)
TABLE 113 FRANCE: VENDOR NEUTRAL ARCHIVE (VNA) & PACS MARKET, BY END USER, 2024–2031 (USD MILLION)
TABLE 114 ITALY: VENDOR NEUTRAL ARCHIVE (VNA) & PACS MARKET, BY PRODUCT TYPE, 2024–2031 (USD MILLION)
TABLE 115 ITALY: VENDOR NEUTRAL ARCHIVE (VNA) MARKET, BY PRODUCT TYPE, 2024–2031 (USD MILLION)
TABLE 116 ITALY: PACS MARKET, BY PRODUCT TYPE, 2024–2031 (USD MILLION)
TABLE 117 ITALY: VENDOR NEUTRAL ARCHIVE (VNA) & PACS MARKET, BY MODALITY, 2024–2031 (USD MILLION)
TABLE 118 ITALY: VENDOR NEUTRAL ARCHIVE (VNA) & PACS MARKET, BY DEPLOYMENT MODEL, 2024–2031 (USD MILLION)
TABLE 119 ITALY: VENDOR NEUTRAL ARCHIVE (VNA) & PACS MARKET, BY VENDOR TYPE, 2024–2031 (USD MILLION)
TABLE 120 ITALY: VENDOR NEUTRAL ARCHIVE (VNA) & PACS MARKET, BY APPLICATION, 2024–2031 (USD MILLION)
TABLE 121 ITALY: VENDOR NEUTRAL ARCHIVE (VNA) & PACS MARKET, BY END USER, 2024–2031 (USD MILLION)
TABLE 122 SPAIN: VENDOR NEUTRAL ARCHIVE (VNA) & PACS MARKET, BY PRODUCT TYPE, 2024–2031 (USD MILLION)
TABLE 123 SPAIN: VENDOR NEUTRAL ARCHIVE (VNA) MARKET, BY PRODUCT TYPE, 2024–2031 (USD MILLION)
TABLE 124 SPAIN: PACS MARKET, BY PRODUCT TYPE, 2024–2031 (USD MILLION)
TABLE 125 SPAIN: VENDOR NEUTRAL ARCHIVE (VNA) & PACS MARKET, BY MODALITY, 2024–2031 (USD MILLION)
TABLE 126 SPAIN: VENDOR NEUTRAL ARCHIVE (VNA) & PACS MARKET, BY DEPLOYMENT MODEL, 2024–2031 (USD MILLION)
TABLE 127 SPAIN: VENDOR NEUTRAL ARCHIVE (VNA) & PACS MARKET, BY VENDOR TYPE, 2024–2031 (USD MILLION)
TABLE 128 SPAIN: VENDOR NEUTRAL ARCHIVE (VNA) & PACS MARKET, BY APPLICATION, 2024–2031 (USD MILLION)
TABLE 129 SPAIN: VENDOR NEUTRAL ARCHIVE (VNA) & PACS MARKET, BY END USER, 2024–2031 (USD MILLION)
TABLE 130 REST OF EUROPE: VENDOR NEUTRAL ARCHIVE (VNA) & PACS MARKET, BY PRODUCT TYPE, 2024–2031 (USD MILLION)
TABLE 131 REST OF EUROPE: VENDOR NEUTRAL ARCHIVE (VNA) MARKET, BY PRODUCT TYPE, 2024–2031 (USD MILLION)
TABLE 132 REST OF EUROPE: PACS MARKET, BY PRODUCT TYPE, 2024–2031 (USD MILLION)
TABLE 133 REST OF EUROPE: VENDOR NEUTRAL ARCHIVE (VNA) & PACS MARKET, BY MODALITY, 2024–2031 (USD MILLION)
TABLE 134 REST OF EUROPE: VENDOR NEUTRAL ARCHIVE (VNA) & PACS MARKET, BY DEPLOYMENT MODEL, 2024–2031 (USD MILLION)
TABLE 135 REST OF EUROPE: VENDOR NEUTRAL ARCHIVE (VNA) & PACS MARKET, BY VENDOR TYPE, 2024–2031 (USD MILLION)
TABLE 136 REST OF EUROPE: VENDOR NEUTRAL ARCHIVE (VNA) & PACS MARKET, BY APPLICATION, 2024–2031 (USD MILLION)
TABLE 137 REST OF EUROPE: VENDOR NEUTRAL ARCHIVE (VNA) & PACS MARKET, BY END USER, 2024–2031 (USD MILLION)
TABLE 138 ASIA PACIFIC: VENDOR NEUTRAL ARCHIVE (VNA) & PACS MARKET, BY COUNTRY/REGION, 2024–2031 (USD MILLION)
TABLE 139 ASIA PACIFIC: VENDOR NEUTRAL ARCHIVE (VNA) & PACS MARKET, BY PRODUCT TYPE, 2024–2031 (USD MILLION)
TABLE 140 ASIA PACIFIC: VENDOR NEUTRAL ARCHIVE (VNA) MARKET, BY PRODUCT TYPE, 2024–2031 (USD MILLION)
TABLE 141 ASIA PACIFIC: PACS MARKET, BY PRODUCT TYPE, 2024–2031 (USD MILLION)
TABLE 142 ASIA PACIFIC: VENDOR NEUTRAL ARCHIVE (VNA) & PACS MARKET, BY MODALITY, 2024–2031 (USD MILLION)
TABLE 143 ASIA PACIFIC: VENDOR NEUTRAL ARCHIVE (VNA) & PACS MARKET, BY DEPLOYMENT MODEL, 2024–2031 (USD MILLION)
TABLE 144 ASIA PACIFIC: VENDOR NEUTRAL ARCHIVE (VNA) & PACS MARKET, BY VENDOR TYPE, 2024–2031 (USD MILLION)
TABLE 145 ASIA PACIFIC: VENDOR NEUTRAL ARCHIVE (VNA) & PACS MARKET, BY APPLICATION, 2024–2031 (USD MILLION)
TABLE 146 ASIA PACIFIC: VENDOR NEUTRAL ARCHIVE (VNA) & PACS MARKET, BY END USER, 2024–2031 (USD MILLION)
TABLE 147 JAPAN: VENDOR NEUTRAL ARCHIVE (VNA) & PACS MARKET, BY PRODUCT TYPE, 2024–2031 (USD MILLION)
TABLE 148 JAPAN: VENDOR NEUTRAL ARCHIVE (VNA) MARKET, BY PRODUCT TYPE, 2024–2031 (USD MILLION)
TABLE 149 JAPAN: PACS MARKET, BY PRODUCT TYPE, 2024–2031 (USD MILLION)
TABLE 150 JAPAN: VENDOR NEUTRAL ARCHIVE (VNA) & PACS MARKET, BY MODALITY, 2024–2031 (USD MILLION)
TABLE 151 JAPAN: VENDOR NEUTRAL ARCHIVE (VNA) & PACS MARKET, BY DEPLOYMENT MODEL, 2024–2031 (USD MILLION)
TABLE 152 JAPAN: VENDOR NEUTRAL ARCHIVE (VNA) & PACS MARKET, BY VENDOR TYPE, 2024–2031 (USD MILLION)
TABLE 153 JAPAN: VENDOR NEUTRAL ARCHIVE (VNA) & PACS MARKET, BY APPLICATION, 2024–2031 (USD MILLION)
TABLE 154 JAPAN: VENDOR NEUTRAL ARCHIVE (VNA) & PACS MARKET, BY END USER, 2024–2031 (USD MILLION)
TABLE 155 CHINA: VENDOR NEUTRAL ARCHIVE (VNA) & PACS MARKET, BY PRODUCT TYPE, 2024–2031 (USD MILLION)
TABLE 156 CHINA: VENDOR NEUTRAL ARCHIVE (VNA) MARKET, BY PRODUCT TYPE, 2024–2031 (USD MILLION)
TABLE 157 CHINA: PACS MARKET, BY PRODUCT TYPE, 2024–2031 (USD MILLION)
TABLE 158 CHINA: VENDOR NEUTRAL ARCHIVE (VNA) & PACS MARKET, BY MODALITY, 2024–2031 (USD MILLION)
TABLE 159 CHINA: VENDOR NEUTRAL ARCHIVE (VNA) & PACS MARKET, BY DEPLOYMENT MODEL, 2024–2031 (USD MILLION)
TABLE 160 CHINA: VENDOR NEUTRAL ARCHIVE (VNA) & PACS MARKET, BY VENDOR TYPE, 2024–2031 (USD MILLION)
TABLE 161 CHINA: VENDOR NEUTRAL ARCHIVE (VNA) & PACS MARKET, BY APPLICATION, 2024–2031 (USD MILLION)
TABLE 162 CHINA: VENDOR NEUTRAL ARCHIVE (VNA) & PACS MARKET, BY END USER, 2024–2031 (USD MILLION)
TABLE 163 INDIA: VENDOR NEUTRAL ARCHIVE (VNA) & PACS MARKET, BY PRODUCT TYPE, 2024–2031 (USD MILLION)
TABLE 164 INDIA: VENDOR NEUTRAL ARCHIVE (VNA) MARKET, BY PRODUCT TYPE, 2024–2031 (USD MILLION)
TABLE 165 INDIA: PACS MARKET, BY PRODUCT TYPE, 2024–2031 (USD MILLION)
TABLE 166 INDIA: VENDOR NEUTRAL ARCHIVE (VNA) & PACS MARKET, BY MODALITY, 2024–2031 (USD MILLION)
TABLE 167 INDIA: VENDOR NEUTRAL ARCHIVE (VNA) & PACS MARKET, BY DEPLOYMENT MODEL, 2024–2031 (USD MILLION)
TABLE 168 INDIA: VENDOR NEUTRAL ARCHIVE (VNA) & PACS MARKET, BY VENDOR TYPE, 2024–2031 (USD MILLION)
TABLE 169 INDIA: VENDOR NEUTRAL ARCHIVE (VNA) & PACS MARKET, BY APPLICATION, 2024–2031 (USD MILLION)
TABLE 170 INDIA: VENDOR NEUTRAL ARCHIVE (VNA) & PACS MARKET, BY END USER, 2024–2031 (USD MILLION)
TABLE 171 REST OF ASIA PACIFIC: VENDOR NEUTRAL ARCHIVE (VNA) & PACS MARKET, BY PRODUCT TYPE, 2024–2031 (USD MILLION)
TABLE 172 REST OF ASIA PACIFIC: VENDOR NEUTRAL ARCHIVE (VNA) MARKET, BY PRODUCT TYPE, 2024–2031 (USD MILLION)
TABLE 173 REST OF ASIA PACIFIC: PACS MARKET, BY PRODUCT TYPE, 2024–2031 (USD MILLION)
TABLE 174 REST OF ASIA PACIFIC: VENDOR NEUTRAL ARCHIVE (VNA) & PACS MARKET, BY MODALITY, 2024–2031 (USD MILLION)
TABLE 175 REST OF ASIA PACIFIC: VENDOR NEUTRAL ARCHIVE (VNA) & PACS MARKET, BY DEPLOYMENT MODEL, 2024–2031 (USD MILLION)
TABLE 176 REST OF ASIA PACIFIC: VENDOR NEUTRAL ARCHIVE (VNA) & PACS MARKET, BY VENDOR TYPE, 2024–2031 (USD MILLION)
TABLE 177 REST OF ASIA PACIFIC: VENDOR NEUTRAL ARCHIVE (VNA) & PACS MARKET, BY APPLICATION, 2024–2031 (USD MILLION)
TABLE 178 REST OF ASIA PACIFIC: VENDOR NEUTRAL ARCHIVE (VNA) & PACS MARKET, BY END USER, 2024–2031 (USD MILLION)
TABLE 179 LATIN AMERICA: VENDOR NEUTRAL ARCHIVE (VNA) & PACS MARKET, BY COUNTRY/REGION, 2024–2031 (USD MILLION)
TABLE 180 LATIN AMERICA: VENDOR NEUTRAL ARCHIVE (VNA) & PACS MARKET, BY PRODUCT TYPE, 2024–2031 (USD MILLION)
TABLE 181 LATIN AMERICA: VENDOR NEUTRAL ARCHIVE (VNA) MARKET, BY PRODUCT TYPE, 2024–2031 (USD MILLION)
TABLE 182 LATIN AMERICA: PACS MARKET, BY PRODUCT TYPE, 2024–2031 (USD MILLION)
TABLE 183 LATIN AMERICA: VENDOR NEUTRAL ARCHIVE (VNA) & PACS MARKET, BY MODALITY, 2024–2031 (USD MILLION)
TABLE 184 LATIN AMERICA: VENDOR NEUTRAL ARCHIVE (VNA) & PACS MARKET, BY DEPLOYMENT MODEL, 2024–2031 (USD MILLION)
TABLE 185 LATIN AMERICA: VENDOR NEUTRAL ARCHIVE (VNA) & PACS MARKET, BY VENDOR TYPE, 2024–2031 (USD MILLION)
TABLE 186 LATIN AMERICA: VENDOR NEUTRAL ARCHIVE (VNA) & PACS MARKET, BY APPLICATION, 2024–2031 (USD MILLION)
TABLE 187 LATIN AMERICA: VENDOR NEUTRAL ARCHIVE (VNA) & PACS MARKET, BY END USER, 2024–2031 (USD MILLION)
TABLE 188 BRAZIL: VENDOR NEUTRAL ARCHIVE (VNA) & PACS MARKET, BY PRODUCT TYPE, 2024–2031 (USD MILLION)
TABLE 189 BRAZIL: VENDOR NEUTRAL ARCHIVE (VNA) MARKET, BY PRODUCT TYPE, 2024–2031 (USD MILLION)
TABLE 190 BRAZIL: PACS MARKET, BY PRODUCT TYPE, 2024–2031 (USD MILLION)
TABLE 191 BRAZIL: VENDOR NEUTRAL ARCHIVE (VNA) & PACS MARKET, BY MODALITY, 2024–2031 (USD MILLION)
TABLE 192 BRAZIL: VENDOR NEUTRAL ARCHIVE (VNA) & PACS MARKET, BY DEPLOYMENT MODEL, 2024–2031 (USD MILLION)
TABLE 193 BRAZIL: VENDOR NEUTRAL ARCHIVE (VNA) & PACS MARKET, BY VENDOR TYPE, 2024–2031 (USD MILLION)
TABLE 194 BRAZIL: VENDOR NEUTRAL ARCHIVE (VNA) & PACS MARKET, BY APPLICATION, 2024–2031 (USD MILLION)
TABLE 195 BRAZIL: VENDOR NEUTRAL ARCHIVE (VNA) & PACS MARKET, BY END USER, 2024–2031 (USD MILLION)
TABLE 196 MEXICO: VENDOR NEUTRAL ARCHIVE (VNA) & PACS MARKET, BY PRODUCT TYPE, 2024–2031 (USD MILLION)
TABLE 197 MEXICO: VENDOR NEUTRAL ARCHIVE (VNA) MARKET, BY PRODUCT TYPE, 2024–2031 (USD MILLION)
TABLE 198 MEXICO: PACS MARKET, BY PRODUCT TYPE, 2024–2031 (USD MILLION)
TABLE 199 MEXICO: VENDOR NEUTRAL ARCHIVE (VNA) & PACS MARKET, BY MODALITY, 2024–2031 (USD MILLION)
TABLE 200 MEXICO: VENDOR NEUTRAL ARCHIVE (VNA) & PACS MARKET, BY DEPLOYMENT MODEL, 2024–2031 (USD MILLION)
TABLE 201 MEXICO: VENDOR NEUTRAL ARCHIVE (VNA) & PACS MARKET, BY VENDOR TYPE, 2024–2031 (USD MILLION)
TABLE 202 MEXICO: VENDOR NEUTRAL ARCHIVE (VNA) & PACS MARKET, BY APPLICATION, 2024–2031 (USD MILLION)
TABLE 203 MEXICO: VENDOR NEUTRAL ARCHIVE (VNA) & PACS MARKET, BY END USER, 2024–2031 (USD MILLION)
TABLE 204 REST OF LATIN AMERICA: VENDOR NEUTRAL ARCHIVE (VNA) & PACS MARKET, BY PRODUCT TYPE, 2024–2031 (USD MILLION)
TABLE 205 REST OF LATIN AMERICA: VENDOR NEUTRAL ARCHIVE (VNA) MARKET, BY PRODUCT TYPE, 2024–2031 (USD MILLION)
TABLE 206 REST OF LATIN AMERICA: PACS MARKET, BY PRODUCT TYPE, 2024–2031 (USD MILLION)
TABLE 207 REST OF LATIN AMERICA: VENDOR NEUTRAL ARCHIVE (VNA) & PACS MARKET, BY MODALITY, 2024–2031 (USD MILLION)
TABLE 208 REST OF LATIN AMERICA: VENDOR NEUTRAL ARCHIVE (VNA) & PACS MARKET, BY DEPLOYMENT MODEL, 2024–2031 (USD MILLION)
TABLE 209 REST OF LATIN AMERICA: VENDOR NEUTRAL ARCHIVE (VNA) & PACS MARKET, BY VENDOR TYPE, 2024–2031 (USD MILLION)
TABLE 210 REST OF LATIN AMERICA: VENDOR NEUTRAL ARCHIVE (VNA) & PACS MARKET, BY APPLICATION, 2024–2031 (USD MILLION)
TABLE 211 REST OF LATIN AMERICA: VENDOR NEUTRAL ARCHIVE (VNA) & PACS MARKET, BY END USER, 2024–2031 (USD MILLION)
TABLE 212 MIDDLE EAST & AFRICA: VENDOR NEUTRAL ARCHIVE (VNA) & PACS MARKET, BY COUNTRY/REGION, 2024–2031 (USD MILLION)
TABLE 213 MIDDLE EAST & AFRICA: VENDOR NEUTRAL ARCHIVE (VNA) & PACS MARKET, BY PRODUCT TYPE, 2024–2031 (USD MILLION)
TABLE 214 MIDDLE EAST & AFRICA: VENDOR NEUTRAL ARCHIVE (VNA) MARKET, BY PRODUCT TYPE, 2024–2031 (USD MILLION)
TABLE 215 MIDDLE EAST & AFRICA: PACS MARKET, BY PRODUCT TYPE, 2024–2031 (USD MILLION)
TABLE 216 MIDDLE EAST & AFRICA: VENDOR NEUTRAL ARCHIVE (VNA) & PACS MARKET, BY MODALITY, 2024–2031 (USD MILLION)
TABLE 217 MIDDLE EAST & AFRICA: VENDOR NEUTRAL ARCHIVE (VNA) & PACS MARKET, BY DEPLOYMENT MODEL, 2024–2031 (USD MILLION)
TABLE 218 MIDDLE EAST & AFRICA: VENDOR NEUTRAL ARCHIVE (VNA) & PACS MARKET, BY VENDOR TYPE, 2024–2031 (USD MILLION)
TABLE 219 MIDDLE EAST & AFRICA: VENDOR NEUTRAL ARCHIVE (VNA) & PACS MARKET, BY APPLICATION, 2024–2031 (USD MILLION)
TABLE 220 MIDDLE EAST & AFRICA: VENDOR NEUTRAL ARCHIVE (VNA) & PACS MARKET, BY END USER, 2024–2031 (USD MILLION)
TABLE 221 GCC COUNTRIES: VENDOR NEUTRAL ARCHIVE (VNA) & PACS MARKET, BY PRODUCT TYPE, 2024–2031 (USD MILLION)
TABLE 222 GCC COUNTRIES: VENDOR NEUTRAL ARCHIVE (VNA) MARKET, BY PRODUCT TYPE, 2024–2031 (USD MILLION)
TABLE 223 GCC COUNTRIES: PACS MARKET, BY PRODUCT TYPE, 2024–2031 (USD MILLION)
TABLE 224 GCC COUNTRIES: VENDOR NEUTRAL ARCHIVE (VNA) & PACS MARKET, BY MODALITY, 2024–2031 (USD MILLION)
TABLE 225 GCC COUNTRIES: VENDOR NEUTRAL ARCHIVE (VNA) & PACS MARKET, BY DEPLOYMENT MODEL, 2024–2031 (USD MILLION)
TABLE 226 GCC COUNTRIES: VENDOR NEUTRAL ARCHIVE (VNA) & PACS MARKET, BY VENDOR TYPE, 2024–2031 (USD MILLION)
TABLE 227 GCC COUNTRIES: VENDOR NEUTRAL ARCHIVE (VNA) & PACS MARKET, BY APPLICATION, 2024–2031 (USD MILLION)
TABLE 228 GCC COUNTRIES: VENDOR NEUTRAL ARCHIVE (VNA) & PACS MARKET, BY END USER, 2024–2031 (USD MILLION)
TABLE 229 REST OF MIDDLE EAST AND AFRICA: VENDOR NEUTRAL ARCHIVE (VNA) & PACS MARKET, BY PRODUCT TYPE, 2024–2031 (USD MILLION)
TABLE 230 REST OF MIDDLE EAST AND AFRICA: VENDOR NEUTRAL ARCHIVE (VNA) MARKET, BY PRODUCT TYPE, 2024–2031 (USD MILLION)
TABLE 231 REST OF MIDDLE EAST AND AFRICA: PACS MARKET, BY PRODUCT TYPE, 2024–2031 (USD MILLION)
TABLE 232 REST OF MIDDLE EAST AND AFRICA: VENDOR NEUTRAL ARCHIVE (VNA) & PACS MARKET, BY MODALITY, 2024–2031 (USD MILLION)
TABLE 233 REST OF MIDDLE EAST AND AFRICA: VENDOR NEUTRAL ARCHIVE (VNA) & PACS MARKET, BY DEPLOYMENT MODEL, 2024–2031 (USD MILLION)
TABLE 234 REST OF MIDDLE EAST AND AFRICA: VENDOR NEUTRAL ARCHIVE (VNA) & PACS MARKET, BY VENDOR TYPE, 2024–2031 (USD MILLION)
TABLE 235 REST OF MIDDLE EAST AND AFRICA: VENDOR NEUTRAL ARCHIVE (VNA) & PACS MARKET, BY APPLICATION, 2024–2031 (USD MILLION)
TABLE 236 REST OF MIDDLE EAST AND AFRICA: VENDOR NEUTRAL ARCHIVE (VNA) & PACS MARKET, BY END USER, 2024–2031 (USD MILLION)
TABLE 237 OVERVIEW OF STRATEGIES ADOPTED BY KEY PLAYERS IN VENDOR NEUTRAL ARCHIVE (VNA) & PACS MARKET, JANUARY 2023–APRIL 2026
TABLE 238 VENDOR NEUTRAL ARCHIVE (VNA) & PACS MARKET: DEGREE OF COMPETITION
TABLE 239 VENDOR NEUTRAL ARCHIVE (VNA) & PACS MARKET: PRODUCT FOOTPRINT, 2025
TABLE 240 VENDOR NEUTRAL ARCHIVE (VNA) & PACS MARKET: DEPLOYMENT FOOTPRINT, 2025
TABLE 241 VENDOR NEUTRAL ARCHIVE (VNA) & PACS MARKET: END USER FOOTPRINT, 2025
TABLE 242 VENDOR NEUTRAL ARCHIVE (VNA) & PACS MARKET: REGIONAL FOOTPRINT, 2025
TABLE 243 VENDOR NEUTRAL ARCHIVE (VNA) & PACS MARKET: DETAILED LIST OF KEY STARTUPS/SMES, 2025
TABLE 244 VENDOR NEUTRAL ARCHIVE (VNA) & PACS MARKET: COMPETITIVE BENCHMARKING OF STARTUPS/SMES, 2025
TABLE 245 VENDOR NEUTRAL ARCHIVE (VNA) & PACS MARKET: PRODUCT LAUNCHES & UPGRADES, JANUARY 2023–APRIL 2026
TABLE 246 VENDOR NEUTRAL ARCHIVE (VNA) & PACS MARKET: DEALS, JANUARY 2023–APRIL 2026
TABLE 247 VENDOR NEUTRAL ARCHIVE (VNA) & PACS MARKET: OTHER DEVELOPMENTS, JANUARY 2023–APRIL 2026
TABLE 248 AGFA-GEVAERT GROUP: BUSINESS OVERVIEW
TABLE 249 AGFA-GEVAERT GROUP: SOLUTIONS OFFERED
TABLE 250 AGFA-GEVAERT GROUP: DEALS
TABLE 251 FUJIFILM HOLDINGS CORPORATION: COMPANY OVERVIEW
TABLE 252 FUJIFILM HOLDINGS CORPORATION: SOLUTIONS OFFERED
TABLE 253 FUJIFILM HOLDINGS CORPORATION: DEALS
TABLE 254 FUJIFILM HOLDINGS CORPORATION: OTHER DEVELOPMENTS
TABLE 255 SECTRA AB: BUSINESS OVERVIEW
TABLE 256 SECTRA AB: SOLUTIONS OFFERED
TABLE 257 GE HEALTHCARE: BUSINESS OVERVIEW
TABLE 258 GE HEALTHCARE: SOLUTIONS OFFERED
TABLE 259 GE HEALTHCARE: PRODUCTS LAUNCHES
TABLE 260 GE HEALTHCARE: DEALS
TABLE 261 MERATIVE: BUSINESS OVERVIEW
TABLE 262 MERATIVE: SOLUTIONS OFFERED
TABLE 263 MERATIVE: DEALS
TABLE 264 KONINKLIJKE PHILIPS N.V.: BUSINESS OVERVIEW
TABLE 265 KONINKLIJKE PHILIPS N.V.: SOLUTIONS OFFERED
TABLE 266 KONINKLIJKE PHILIPS N.V.: PRODUCT LAUNCHES
TABLE 267 KONINKLIJKE PHILIPS N.V.: DEALS
TABLE 268 CANON MEDICAL SYSTEMS CORPORATION: COMPANY OVERVIEW
TABLE 269 CANON MEDICAL SYSTEMS CORPORATION: SOLUTIONS OFFERED
TABLE 270 CANON MEDICAL SYSTEMS CORPORATION: DEALS
TABLE 271 PAXERAHEALTH: BUSINESS OVERVIEW
TABLE 272 PAXERAHEALTH: SOLUTIONS OFFERED
TABLE 273 NOVARAD CORPORATION: BUSINESS OVERVIEW
TABLE 274 NOVARAD CORPORATION: SOLUTIONS OFFERED
TABLE 275 HYLAND SOFTWARE, INC.: BUSINESS OVERVIEW
TABLE 276 HYLAND SOFTWARE, INC.: SOLUTIONS OFFERED
TABLE 277 HYLAND SOFTWARE, INC.: DEALS
TABLE 278 SIEMENS HEALTHCARE LIMITED: BUSINESS OVERVIEW
TABLE 279 SIEMENS HEALTHCARE LIMITED: SOLUTIONS OFFERED
TABLE 280 SIEMENS HEALTHCARE LIMITED: DEALS
TABLE 281 BRIDGEHEAD SOFTWARE LTD.: BUSINESS OVERVIEW
TABLE 282 BRIDGEHEAD SOFTWARE LTD.: SOLUTIONS OFFERED
TABLE 283 CANOPY PARTNERS: BUSINESS OVERVIEW
TABLE 284 CANOPY PARTNERS: SOLUTIONS OFFERED
TABLE 285 CRELIOHEALTH INC.: BUSINESS OVERVIEW
TABLE 286 CRELIOHEALTH INC.: SOLUTIONS OFFERED
TABLE 287 ASPYRA, LLC: BUSINESS OVERVIEW
TABLE 288 ASPYRA, LLC: SOLUTIONS OFFERED
TABLE 289 POSTDICOM: BUSINESS OVERVIEW
TABLE 290 POSTDICOM: SOLUTIONS OFFERED
TABLE 291 MEDICASOFT: BUSINESS OVERVIEW
TABLE 292 MEDICASOFT: SOLUTIONS OFFERED
TABLE 293 ESAOTE SPA.: BUSINESS OVERVIEW
TABLE 294 ESAOTE SPA: SOLUTIONS OFFERED
TABLE 295 ESAOTE SPA: PRODUCT LAUNCHES
TABLE 296 VISUS HEALTH IT GMBH: BUSINESS OVERVIEW
TABLE 297 VISUS HEALTH IT GMBH: SOLUTIONS OFFERED
By bringing desired changes in the clinical workflow and by improving the unification and accessibility of data, VNAs have the capability to provide enhanced patient care. VNAs provide timely access to patient data at the point-of-care. They also offer early access to professional help for patients, they help with faster decision making, and they bring about transparency. Another factor that is driving the need for patient-centric systems is rising patient awareness. The increased awareness of patients with regards to healthcare has greatly helped them to make decisions, especially in the management and treatment of chronic conditions. If the patient has access to his/her personal health information that is shared across public and private clinical organizations, it could enable healthcare providers and patients to collaborate and make informed decisions.
Many EHR systems that are marketed today are featured as "patient portals" that give individuals immediate access to their own lab results, X-ray reports, list of medications, and other information. Similar strategies can be applied to VNAs that would allow patients to communicate securely via e-mail with their physicians and other medical personnel. Thus, installation of VNAs that are developed with the idea of delivering high-quality patient care is poised to increase amongst organizations.
The multi-department VNA segment accounts for the largest share—XX%—of the global VNA market in 2013. This segment is expected to reach $XX million by 2018 at a CAGR of XX% for the same period. Cross-departmental interoperability is seen as the first step to achieving communication within a hospital setting, a factor that explains the largest share and highest CAGR of this segment. The segment is closely followed by departmental VNAs contributing XX% to the market. This procurement model is generally adopted in radiology departments with the view to test a VNA for their department so as to take a further decision of scaling up to a multi-departmental level. A VNA at a multi-site level allows VNA adoption across various hospital enterprises, the trend for which is growing at a rapid pace.
North America commands the largest share—XX%—of the global VNA market at an estimated $XX million in 2013. It is expected to reach $XX million by 2018, at a CAGR of XX% from 2013 to 2018. This growth in the North American market is because of the mandates imposed by the federal government for image enablement of EHRs via Meaningful Use of the HITECH (Healthcare Information Technology for Economical and Clinical Health) Act. The rising imaging volume in the U.S.—owing to the aging population and subsequent demand for diagnostic imaging—is another major reason for its large share.
Europe, on the other hand, has the second-highest share in the VNA market and is the fastest growing region for VNA adoption. The healthcare structure in European countries like U.K., Germany, and France encourages VNA deployment on a multi-site level rather than on a departmental level. Deployment of VNAs on a large scale is expected to bring higher revenues to the European market, thus substantiating the higher growth. Moreover, the European market is more advanced than the U.S. market in terms of standards followed. The European market has begun to adopt the XDS-based VNA while the U.S. market, on the other hand, still lags behind technologically, with the traditional DICOM standard-based VNA still accounting for the largest share in the U.S.
